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1.1. Susceptibility to cardiotoxicity 
 
Cardiotoxicity induced by antineoplastic drugs is becoming a significant health 
problem for patients who have received or receiving cancer treatment. Nowadays, it is 
the major leading cause of long-term morbidity and mortality among cancer survivors1. 
It is not known who is going to be more susceptible to develop cardiotoxicity under the 
same treatment regimen. Individual susceptibility to therapy-related cardiotoxicity, as 
well as other complex diseases, is a consequence of interactions between genetic and 
environmental factors. Also, currently approved biomarkers appear when the damage 
is already done, so, there is a necessity to identify early, more sensitive and specific 
novel markers as well as predict potential individuals susceptible to cardiotoxicity before 
the clinical manifestations appear2. This section focuses on what is known about in 
genetics and cardiac biomarkers which may help to predict cardiotoxic events in 
oncological patients.  
 
1.1.1. Prediction by genetic approach 
 
This approach offers the opportunity to identify early markers of cardiotoxicity, 
revealing the potential genetic variants that may contribute to drug response in each 
patient before starting the treatment and develop cardioprotective agents for future 
oncological treatment. 
 
• Chemotherapy treatment: Anthracyclines 
 
Single nucleotide polymorphism (SNP) associated with anthracyclines-induced 
cardiotoxicity include, among others, those related to NAD(P)H oxidase and doxorubicin 
transporter genes3–5. Chronic cardiotoxicity has been associated with the SNP rs1883112 
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in the NCF4 gene of the NAD(P)H oxidase p40phox subunit in several studies, including 
different types of oncological diseases and treatments3,6 and also with cardiac fibrosis 
in a study developed by Cascales.et.al4. By contrast, acute cardiotoxicity was associated 
with an SNP in the CYBA gene, rs4673, corresponding to the NAD(P)H oxidase p22phox 
subunit3. There are also several genes related to free radical generation, in particular, 
the P450 oxidoreductase gene (POR) whose SNPs rs2868177, rs13240755, rs4732513 
were associated with the functional decrease of left ventricular ejection fraction (LVEF) 
in a study performed in more than 250 patients after receiving antineoplastic treatment 
with daunorubicin and doxorubicin7. 
Interestingly, recent studies are focused on discovering which kinases could be 
used as regulators of the beat rate in cardiomyocytes. Lamore. S et al.8 described how 
inhibiting the expression of RPS6KB gene that encodes p70s6k protein and MAP4K2 
whose expressed proteins specifically activates MAPK, is translated in short action 
potential duration (APD) in cardiomyocytes as well as the short duration of Ca2+ flux and 
contractility transients. By contrast, knocking down RPS6KA3 and IKBKE leads to an 
increase in the amplitude of the Ca2+ transient and  thus reduced the beat rate8.  
In pediatric patients has been identify several genes with significant SNPs implied 
in DNA damage, drug transport, oxidative stress, sarcomere dysfunction and iron 
metabolism9. Retinoid acid receptor gamma (RARG) variant (rs2229774) confers 
susceptibility to CDA through decreasing the repression to (TOP)2B. That leads to 
increase the levels of this protein which added to the effect of doxorubicin rise the 
double strand breaks in DNA10. UDP‐glucuronosyltransferase (UGT)1A6 (rs17863783) 
variant makes the anthracycline metabolites glucuronidate and reduct, increasing the 
levels of toxic metabolites in the cytoplasm of the cardiomyocytes predispose them to 
CDA11. The variant of the gene G‐protein‐coupled receptor (GPR)35 (rs12468485) 
described by Ruiz‐Pinto et al.12 was related to a decrease in cell viability and oxidative 
stress after exposure to anthracyclines treatment.  CUGBP Elav‐like family member 
(CELF)4 variant (rs12468485) regulates the alternative splicing of Troponin T gene 
(TNNT2) leading to an expression of embryonic forms of cardiac troponin T which are 
developmentally innapropiate13. Mutations in the metalloproteinase-disintegrin-like 
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HF3 increases the iron concentration in the cell producing higher concentrations of 
hydroxyl radicals causing DNA damage, among others9. 
 
• Proteasome inhibitors 
 
In recent years there is an increasing interest in the genes that participate in CDA 
induced by new oncological treatments such as proteasome inhibitors. Until now, the 
studies seem to be focus on processes related to cell survival and apotosis but, not so 
many studies have examined genes related to susceptibility to suffer cardiotoxicity so 
far. There are only a couple interesting studies:  
The exact mechanism by Bortezomib interacts with the cardiac activity is 
unknown and there are not accurate studies in the genes related to this cardiac side 
effects but it is described that this drug impaired the activation of transcription factor 
Nuclear Factor Ƙappa βeta (NF Ƙβ) important in apoptosis genes and cell survival14.  
Furthermore, in 2017, Iman F et al.15 described that an imbalance expression of 
genes such as Mayor Histocompatibility Complex α (α-MHC), Mayor Histocompatibility 
Complex β (β-MHC) and Brain Natriuretic Peptide (BNP) cause disorganization in the 
myocytes and  cardiac hypertrophy under Carfilzomib treatment in mice models. The 
same study describe how expression levels of NF Ƙβ increases and p53 gene expression 
significantly decrease in mice treated with this compound15.  
 
1.1.2. Prediction by cardiac biomarkers approach 
 
There is a growing interest in biomarkers as an early detection indicator of 
cardiotoxicity during oncological treatment, as a tool for risk prediction before the 
treatment and as a late detection signal of cardiac events in survivor patients. 
Biomarkers are a cheaper alternative method to echocardiography or cardiac magnetic 
imaging and less time consuming to cancer patients, only a blood draw which can be 
arranged by the physician at the same time as the routine blood tests16.  
INTRODUCTION 
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• Troponin I 
 
Troponin I (TnI) and troponin T (TnT) are part of the Troponin protein complex 
involved in the actin-myosin interaction in cardiomyocytes. It is mostly found in the 
sarcomeres. When cardiac damage occurs, there is a significant release of troponins into 
circulation after the sarcomere breakdown. Historically Tns were used as a diagnostic 
tool in different clinical settings as cardiac hypertrophy, acute coronary syndromes, or 
heart failure among others but in the last two decades, the attention is focused on the 
evaluation of oncological settings as detection of cardiac damage due to oncological 
treatment17. Although high levels of troponin are detected in other scenarios such as 
renal failure, several studies prove the utility of these tests. Cardinale et al. conducted a 
temporal study of 240 breast cancer patients who received high doses of 
anthracyclines18. It shows how for seven months, patients with elevated levels of TnI 
had a reduction of LVEF. TnT elevation together with decrease of LVEF, was also 
observed in hematological patients after chemotherapy treatment19. Nowadays, high 
sensitivity troponin measurements help us to detect lower concentrations than 16ng/L, 
as explained in Shah et al.20 The flaw in these studies is that the damage is already done 
when troponins are detected, so nowadays, its predictive power is questioned. 
 
• Brain-type Natriuretic Peptide (BNP) and N-Terminal pro Brain 
natriuretic peptide (NT-pro BNP) 
 
Brain natriuretic peptide and its inactive N-terminal amino acid fragment NT-pro 
BNP are the second most reached in the biomarker list. Both derived from the 
prohormone proBNP synthesize in the cardiomyocytes upon ventricular wall overload 
or stress21, once released in the circulation is cleaved into BNP and NT-pro BNP in a 1:1 





Figure 1. Pathway of NT-proBNP and BNP synthesis from proBNP. 
proBNP is cleved by corin enzyme resulting in two residues. The average time in circulation is 
120 minutes for NT-proBNP (dark green) and 20 min for BNP (orange). 
 
Current guidelines recommend using these two well-known parameters as 
reliable markers of cardiac damage23, and several studies have shown more sensitivity 
than echocardiography studies24. In an exciting study with 204 pediatric patients 
suffering from acute leukemia and treated with anthracyclines, the detection of high NT-
pro BNP levels in the first three months was a predictor of cardiac dysfunction four years 
later25. Another study shows that BNP measurements in the entire course of the 
treatment helped to predict cardiotoxicity in 104 lymphoma and sarcoma patients26. 
Nevertheless, natriuretic peptides have limitations, as with troponin detection, 
small sample size, and lack of ranges references16. Furthermore, the elderly and woman 
population seems to have naturally higher levels of these biomarkers27,28, and recent 
evidence suggests that oncological patients with metastatic complications present an 




Non-coding RNA molecules play an essential role in regulating gene expression 
and other important mechanisms in cardiovascular system30. After the discovery of 
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circulating miRNAs in body fluids, including serum or plasma, they were quickly 
introduced as potential non-invasive diagnostic and prognostic biomarkers in many 
diseases, including cancer31. Despite the initial promising results, miRNA are not still 
validated and approved as clinical biomarkers32, their detection in serum or plasma is 
more complicated than expected, in part due to the lack of standard methods to 
detection and normalization33, and the no consensus on endogenous controls.  
Even though it is still unclear that miRNAs can predict cardiovascular effects, 
several studies carry out on this topic. A recent study shows how the let-7 family is 
implied in several cardiovascular diseases and let-7g is downregulated in doxorubicin-
induced cardiomyopathy34. The miR-125b seems to be a so-called cardio-miR that is 
upregulated in patients suffering from heart failure together with miR-195 and miR-
21435. Higher levels of miR-30 are protective against anthracycline toxicity and in a study 
developed in murine heart exposed to doxorubicin showed that is downregulated 
through GATA-6 which plays a crucial role in heart development36. miR-21 is mainly 
expressed in adult cardiomyocytes where regulates the ERK/MAP kinases pathway in 
cardiac fibroblast but also plays a vital role in cardiac development and regulating cell 
proliferation. Its overexpression after doxorubicin treatment attenuated doxorubicin-
induced apoptosis and when the miRNA is inhibited the apoptosis increased under the 
same treatment regime37. In concrete, its 5’arm, miR-21-5p, is well characterized for its 
contribution to myocardial disease through MAP Kinases signaling in fibroblast38 and, 
more importantly, has been recently described as being upregulated by the oncogene 
HER2, which opens new options for therapies39.  
Therefore, miRNAs seem to be a useful tool in protection, diagnosis, and 
regulation of different mechanisms in cardiomyocytes against oncological treatments. 
There are hundreds of them illustrating their essential regulatory roles in the 
pathogenesis of human diseases. Even though some may have a specific function, others 
do not have a definite pattern, and some studies seem contradictory. The identification 
and characterization of novel dysregulated miRNAs as a potential markers of drug-




1.2. Classification of the cardiotoxicity 
 
For over a decade (2005), the chemotherapeutic agents, which can cause 
cardiotoxicity, have been divided into two main groups40:  
Type I group causes irreversible damage by a cumulative dose in the heart. It can 
also be classified as acute, subacute and chronic depending on the time from the 
initiation of the treatment; acute and subacute when develops up to 2 weeks, and it is 
characterized by arrhythmias, abnormalities in ventricular repolarization and QT 
intervals, and chronic, when appearing, one year after completing the treatment, is a 
severe asymptomatic condition which leads to an irreversible heart failure. Drugs 
included in this group are: anthracyclines (Doxorubicin, Daunorubicin, Epirubicin and 
Idarubicin), alkaline agents, the oldest type of chemotherapy (Cyclosphosphamide, 
Melphalan or cisplatin derivates), taxanes (docetaxel and paclitaxel)  used very 
frequently with anthracyclines in combined treatment, topoisomerase inhibitors, that 
are used in combination with other antineoplastic drugs (tretinoin and vinca alkaloids) 
and antimetabolites, classified as pyrimidine (5-Fluorouracil, Capecitabine or 
Cytarabine) or purine analogs (6-Mercaptopurine). 
Type II or reversible cardiotoxicity include monoclonal antibodies: Trastuzumab, 
Pertuzumab, Bevacizumab and small molecule inhibitors lapatinib and sunitinib.  
characterized by non-cumulative effect and often independent of the administered 
dose41. Symptoms are associated with cardiac dysfunction but no structural damage and 
are reversible in up to 76%42 of the cases.  
According to Witteles et al. 43, this classification has two main flaws; the first one 
is the incorrect term “reversible” in the type II group. After prospective studies about 
the cardiotoxicity of trastuzumab in HER2 breast cancer patients, the long-term effect 
seemed to have as hard effects as anthracyclines. The second flaw is related to the kind 
of cardiotoxicities produced by the oncologic treatments which should be at least nine 
based on the mechanism of action and distint patterns of cardiotoxicity as described in 




1.3. Stages of heart failure during chemotherapy 
 
According to the American College of Cardiology, there are four stages of heart 
failure44: 
-Stage A: pre-heart failure. The patient has a high risk of developing heart failure 
but does not present structural heart disease symptoms. 
-Stage B: pre-heart failure. The patient presents structural heart disease; 
echocardiography shows an ejection fraction of less than 40% but no signs of heart 
failure.  
-Stage C: Structural heart disease with symptoms of heart failure.  
-Stages D and E: refractory heart failure.  
Currently, cardiotoxicity induced by oncological drugs is diagnosed in stages B to C, but 
new clinical outcomes offer diagnosed cardiotoxicity much earlier in Stage A45. 
 
1.4. Proposed diagnostic tools for detection of the cardiotoxicity 
 
In breast cancer survivors older than 65 years old, cardiovascular diseases are 
the primary cause of death46. This fact is due to 2 main factors, first, the direct impact 
of the cancer treatment against the cardiovascular system and second, the lack of 
attention in cardiac care until the first symptoms appear. Furthermore, some studies 
suggest that once the cardiac damage appears, particularly with anthracyclines 
treatment, the complete recovery of left ventricular function only occurs in a minority 
of the patients47. This scenario makes the cancer therapy-related heart failure emerged 
as one of the fields of great interest in cardiology. Now the preferred strategy of 








Echocardiography was started to use in 1970 as a technique to measure the left 
ventricular stroke volumes48. Nowadays, it has emerged as the first method to detect 
cardiotoxicity in oncological patients.  There are two different variations: 
 
• 3D based LVEF 
 
The use of 3D echocardiography-based myocardial strain is one of the methods 
of choice for diagnosis of cancer therapy-related to heart failure. The reason is the wide-
spread availability, excellent reproducibility, and lack of radiation. In 2018 Zang et al.49 
proved it in a study with 142 women treated with anthracyclines. This study is the most 
extensive to date describing temporal changes in breast cancer patients. One of the 
critical conclusions its reaches are the decrease of myocardial strain (circumferential, 
longitudinal, and principal strain) and 3D LVEF after anthracycline treatment when 
compared with a control group. Unfortunately, there is no universal threshold to define 
cancer therapy-related cardiac dysfunction. The European Society of Cardiology in 2016 
established that a decline of 50% of normal left ventricular ejection fraction (LVEF) is 
considered a high reduction in functionality. The disadvantage is the reduced 
availability, is not always clinically accesible50.  
 
• 2D Simpsons LVEF 
 
Although the American Society of Echocardiography recommended this method 
for measuring LVEF51 several studies have shown shortcomings in terms of inter and 
intra variability52. This method is based on a modified biplane Simpson’s technique that 
is based on dividing the LV cavity into a predetermined number of discs, usually 2053. 
This geometric assumption, the inability to detect subtle variation in the heart wall 
motion, and the comparative studies prove that 3D echocardiography is more accurate, 
makes the 3D image acquisition the recommended technique when possible52. 
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1.4.2. Left Ventricular Global Longitudinal Strain (GLS) 
 
This assessment measures the cardiac deformation based on three different 
parameters, longitudinal, radial, and circumferential in two points at the end of the 
systole and the end of diastole. The data can be obtained from echocardiography or 
cardiac magnetic resonance imaging (CMR). GLS has become popular as a useful tool for 
sub-clinical LV dysfunction in oncological patients45 and is considered very accurate 
when used the same processing software across the study. Nowadays, and increase of 
GLS, more than 15% compared with control patients, is considered an abnormal value.  
 
1.4.3. Nuclear Cardiac Imaging (MUGA) 
 
The non-invasive technique, Multiple Gated Acquisition Scan or ERNA, has been 
used since the 1980s to detect left ventricular dysfunction in patients treated with 
anthracyclines54. This method is used to evaluate the ejection fraction of the heart by 
measuring how much blood is pumped into the ventricles of the heart in each heartbeat. 
A small amount of radioactive solution is administered intravenously. The substance has 
an affinity for blood cells and will be detected by the camera as they travel through the 
heart and then derive the LVEF. This technique is not advantageous for patients 
receiving chemotherapy to detect the loss of strength in the heart. Although it is ideal 
in serial exams, the main disadvantage is the exposure of patients to ionizing radiation50. 
 
1.4.4. Cardiac Magnetic Resonance CMR 
 
Sometimes known as a cardiac Magnetic Resonance Imaging (MRI), CMR is non-
invasive cardiac imaging developed in the 21st century. This method is the gold standard 
quantification of LVEF, but its also used for the evaluation of different cancer therapy-
related cardiac toxicity50 as changes in cardiac distorting, vascular assessment, 
pericardial disease, and myocardial inflammation or fibrosis. The technique is based on 
the same basic principles as MRI but with optimization in the use of the cardiovascular 
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system. MRI is a non-invasive tool that is suitable for long monitoring of cancer patients 
and early cardiotoxic detection, as demonstrated in several recent studies55–57. 
The University Hospital of Salamanca has proposed 16 definitions of functional 
cardiac damage based on different degrees. The list of definitions was as follows (Figure 
2):  
Figure 2. List of the 16 definitions of the functional cardiac damage. 
 
 
1.5. Cardiac testing in hiPSCs-CMs 
 
1.5.1. Personalized medicine 
 
As explained previously, although some of the effects of the oncological 
treatments can be predicted, unexpected cardiotoxicity still occurs. Animals models 
have shed light on this issue and are an essential step before going to a clinical trial, but 
differences in physiology, metabolism, or gene expression sometimes make the 
translational interpretation difficult. It is necessary to accurate human in vitro models 
to study the mechanism in detail and desirably in the future to be able to predict the 
susceptibility of the patients before starting the treatment and scale the dose based on 
this data.  
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The discovery of the induced pluripotent stem cells has opened new options to 
save drug screening for cell-based safety and toxicity and allow the pharmaceutical 
companies to move safely from the bench to the clinical trials58. One of the significant 
benefits of using this technology is that it can be produced in vitro in limitless quantities 
and develop the trials in real human models. 
In the concrete case of human induced pluripotent stem cells-derived 
cardiomyocytes (hiPSCs-CMs), with the advances in genome editing, we can create in 
vitro genetic cardiovascular diseases introducing mutations mimicking the human 
disease. This feature is particularly exciting in the pharmacogenomic field in early-stage 
drug candidates59 
However, there are some limitations to the use of hiPSCs-CMs. Functional 
immaturity, homogeneity in the cell culture and lack of 3D architecture are the main 
concerns among researchers60, and over the past few years they have put different 
efforts in developing strategies: the T-tubule development to mature the excitation-
contraction coupling61, the use of 3D tissue engineering62or computational platforms to 
asses in a quantitative way this problem63 to produce more mature like adult-cells.  
But in the near term is the most suitable technology to model diseases, especially 
in the context of the earliest stages or drug discovery processes. 
 
1.5.2. Physiological drug screening 
 
New high throughput methods to quantify the kinetics of excitation and 
contraction make it possible to conduct physiological screening experiments on a large 




Because of their extensive use in oncological treatment, several research groups 
focus their attention on chemotherapy mediated cardiotoxicity. hiPSCs-CMs have 
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revolutionized the study in this field, getting relevant information that can be applied in 
the clinic. One recent study showed that hiPSCs-CMs from breast cancer patients who 
suffered cardiotoxic events during the chemotherapy treatment are more sensitive in 
terms of cell viability, impairment of calcium handling or metabolic function than breast 
cancer patients that after the chemotherapy did not present cardiotoxicity64. In the 
study of Kitani et al.,65 they made an in-depth description about the cardiotoxicity 
produced by Trastuzumab and its seriously effect in the contractility and the use of 
calcium without cardiac death or sarcomere disorganization. This effect is different to 
the indiced by anthracyclines, which causes decrease in cell viability through necrosis 
and apoptosis within hours of administration in the IPSCs-CMs, in agreement with 
human biopsies studies66, that lead to functional effect causing reduced beating rate 
and abnormal patterns67. 
 
• Proteasome inhibitors 
 
Proteasome inhibitors (PIs) in combination with immunomodulators and 
glucocorticoids are currently used in combination in the treatment of multiple myeloma. 
These PIs inhibit the activity of the proteasome leading to the disruption of the ubiquitin 
proteasome system (UPS) the major mechanism of degradation of cytosolic and nuclear 
proteins, consequently, unfolded proteins accumulate in the cell and activate the 
unfolded protein response (UPR) which produce the activation of pro-apoptotic 
cascades and the cell death68. It has been shown that this mechanism also affects the 
cardiac proteasome in sarcomere the reason why several clinical reports have 
mentioned cardiotoxic events69,70. 
All three approved PIs (Bortezomib, Carfilzomib, and Ixazomib) induce 
cardiotoxicity in different degrees in clinic71. Besides, there are three new proteasome 
inhibitors, two of them analogs to Bortezomib and Carfilzomib (Oprozomib and 
Delanzomib) that still need to be studied in their cardiac effects. Testing these new 
compounds in hiPSCs-CMs, as have already done in this work, lead us to have 
preliminary information about the possible cardiac impact in terms of toxicity or 
protection of the treatment.  
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Immunomodulators, including lenalidomide, pomalidomide and thalidomide, 
have shown dramatically increase in thromboembolic effects in combination with PIs72 
and some research groups suggest cytokine levels or genetic factors behind these effects 
but the exact mechanism of action is not clear73.  
 




The breast cancer statistics rates situate this malignancy as the most frequent 
and the second leading cause of death in women worldwide after lung cancer74. In 2018 
there were registered over 2 million new cases, and the number of fatalities were 
around 600.000, which is approximately 15% of all cancers among women75. In the past 
2019 an estimated of 300,000 new cases in women and 2,670 in men according to the 
American Cancer Society76.   
Furthermore, the number of cases is increasing, not only in countries when the 
incidence is always higher as in Europe but also in countries where the rate was 
historically very low as in Asia, Africa, and Latin America77. The hypothesis is that 
undeveloped countries are starting to embrace a lifestyle that encourages the 
development of the disease. This includes sedentarism, obesity, a decrease in the 
number of children, delaying the start of childbearing, or exposure to carcinogenic as in 
developed countries. 
Despite this data, survival is one the highest after melanoma of the skin. 
According to the American Cancer Society78, 90% of people who are diagnosed with 
breast cancer will live for at least five years more, including all types and stages and the 





2.2. Classification of breast cancer tumors 
 
Breast cancer is a heterogeneous disease classified in multiple subtypes. In the 
beginning, the identification of the different subtypes was based on immunochemistry79 
and gene expression79, but currently, several factors are included in this clinical process, 
such as  tumor morphology, tumor size, lymph node metastasis, proliferation marker Ki-
67 and expression of HER2, ER and PR receptors. Later, the pioneering studies conducted 
by Sørlie et al. started to classify the tumor in 5 main groups explained in the next 
section79,80. The rationale underlying such classification was identifying by clustering of 
gene expression among cancer subtypes reflecting the fundamental differences of the 
tumors at the molecular level81. 
 
• Luminal A and B 
 
Both subtypes of breast cancer are hormone-receptor-positive (estrogen-
receptor and/or progesterone-receptor positive) and express luminal cytokeratin 8 
/1882. Luminal A tumors is the most common subtype of breast cancer tumors; are HER2 
negative and have low levels of the protein Ki-67, tend to grow slowly, and are 
associated with better prognosis. At the genome level, these tumors have mutations in 
PI3KCA and MAP3K183. Luminal B tumors are either HER2 positive or negative. These 
tumors are more proliferative (higher Ki-67 values) and the prognosis is slightly worse. 
These tumors show high expression levels of genes related to proliferation, such as 
AURKA, and lower levels of luminal markers, such as FOXA1 or PR84. Luminals tumors 
are the most common subtypes of breast cancer, thus, between60% to 70% of invasive 
ductal carcinomas are luminal85.  
 
• Triple-negative/basal-like breast cancer 
 
These tumors are hormone-receptor negative (estrogen-receptor and 
progesterone-receptor negative) and HER2 negative. Their frequency is between 15% to 
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20% of all tumors. These tumors express basal cytokeratin 5,6,7 and 17, and genes 
related to ERBB286. This subtype of breast cancer is more common in women with BRCA1 
gene mutations87 and younger and African-American women88. The prognosis is worst 





Around 10% to 15% of all breast cancer tumors are HER2 subtype. They are 
hormone-receptor negative (estrogen-receptor and progesterone-receptor negative) 
and overexpressed ErbB2. Several subtypes of breast cancer tumors express HER2, but 
this group presents more mutations. TP53 and PIRKCA appear in 72% and 39% of the 
cases89, intermediate expression of luminal genes ESR1 and PGR, and low expression of 
cytokeratin 5 and FOXC1. These tumors tend to grow faster than luminal cancers and 
have worst prognosis but are typically treated successfully with targeted therapies as 
Trastuzumab, Pertuzumab or novel tyrosine kinase inhibitors as Lapatinib or Neratinib90. 
 
• Normal like breast cancer 
 
This subtype is similar to Luminal A, accounting for 7.8% of the breast cancer 
tumors. It is characterized for being hormone-receptor-positive (estrogen-receptor 
and/or progesterone-receptor positive), HER2 negative. It is the only subtype that 
displays the tumor-initiating stem-cell phenotype with low expression of CD24, high 
expression of CD44, and high expression of vimentin and TWIST191. Its prognosis is 
slightly worse, which means more aggressive than luminal A. 
In an analysis of human and murine breast tumors was discovered the Claudin-
low breast cancer subtype92. This subtype is associated with low expression of cell-cell 
adhesion genes, high expression of epithelial-mesenchymal transition (EMT), and stem 
cell-like related genes expression93. Besides, it presents immune and stromal cell 
infiltration, expressing high levels of PD-L1, reduced proliferation levels. In summary, 
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several studies considered claudin-low tumors as a breast cancer phenotype defining it 
as a heterogeneous tumor, but this classification is not currently applied in clinic. 
 
2.3. Pharmacological treatment of breast cancer 
 
2.3.1. Hormonal therapy 
 
This therapy is based on those tumors which express hormonal receptors. The 
main objective is to reduce the effects of the hormones produced in the patients by 
these receptors. There are three strategies: 
1. Suppression of the hormones produced in the ovary. In premenopausal women, 
the ovary is the highest producer of estrogens, so their suppression leads to a 
decrease in the whole levels. One option is the oophorectomy or, as a less 
aggressive alternative, the use of pharmaceutical agonist of the gonadotropin-
releasing hormone (GnRH) which disrupt the circulating concentration of 
estrogen through their action on the hypothalamus-pituitary axis. Goserelin and 
leuprolide are examples of these compounds94. 
2. Inhibition of the estrogen synthesis. Aromatase inhibitors are currently used in 
the clinics to disrupt the biosynthesis of androgens into estrogens95. The third-
generation compounds are: anastrozole, letrozole (nonsteroidal) and 
exemestane(steroidal)96.  
3. Disruption of binding of a ligand to estrogen receptor: Tamoxifen binds to the 
estrogen receptor-blocking the proliferative effect of estrogen on the mammary 
epithelium. In case of those tumors that do not respond, Fulvestrant is used as 




The main feature in tumor cells is their proliferative status. Chemotherapy drugs 
interfere in essential cellular processes to block proliferation through cell cycle arrest or 
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cell death. However, they are not highly specific and affect healthy tissues specially the 
most proliferative as the mucous membrane in the mouth, hair follicle, intestine, bone 
marrow and germinal cells; that is why cause serious side effects. Some of these drugs 
are: 
1. Alkylating agents. They were the first non-hormonal compounds used as 
oncological treatment. They bind to the DNA strand blocking its replication. 
Some examples are nitrogen mustards (cyclophosphamide), cisplatin, 
nitrosoureas (carmustine, lomustine, and semustine), alkyl sulfonates 
(busulfan), aziridines (thiotepa), and triazines (dacarbazine). 
2. Antimetabolites. They are molecules similar to DNA and RNA components to 
shift the naturally occurring compounds and block the cell’s normal 
metabolic status. They are classified in these groups: folic acid analogues, 
pyrimidine analogues, cytidine analogues and purine analogues.  
3. Anti-Microtube agents. Anti-mitotic agents through the disruption of the 
microtubule dynamics during cell division. Taxanes and Vinca alkaloids have 
this mechanism of action. 
4. Topoisomerase II inhibitors. These inhibitors are split into two classes: Topo 
II catalytic inhibitors which eliminate the enzymatic activity of Topo II, 
blocking the enzyme turnover, belong to this group ICRF 193 and genistein. 
The second group, the Topo II poisons, lead to increase levels of Topo II and 
are named poison because these agents generate “lesion” that includes DNA 
strand breaks and protein covalently bound to DNA not allowing the correct 
replication and transcription. Some examples are doxorubicin, 
epipodophyllotoxins etoposide and teposide98.  
 
The mechanism of action of these compounds are clearly described in Goodman 
& Gilman’s: Pharmacological Basis of Therapeutics99. Anthracyclines and taxanes are 
among the top choices for basal-like metastatic breast cancer and those who resist 
hormone therapy and have never been exposed to the treatment before100. Doxorubicin 
plus docetaxel combination is an approved protocol and widely used in the clinic for the 
last 20 years101. 
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2.3.3. Targeted therapy 
 
These therapies include compounds which target key molecules involved in vital 
mechanisms in the tumor cells. That means fewer side effects in non-tumoral tissues. 
Some of these treatments are: 
1. Receptor ER+ tumors. Apart from hormone therapy, palbociclib, an inhibitor of 
CDK4/6, and everolimus, an inhibitor of the mTOR pathway, are currently 
approved by FDA102. 
2. Receptor ERBB2+ tumors. The currently approved antibodies against this 
receptor are trastuzumab and pertuzumab, humanized monoclonal antibodies 
against different epitopes in the extracellular region in ERBB2; and lapatinib, a 
tyrosine kinase inhibitor against the kinase domain of EGFR and ERBB2. A new 
strategy is the use of immunoconjugates, which includes a toxic particle in the 
antibody. In ERBB2 tumors, T-DM1 is approved as a combination of trastuzumab 
and emtansine, a microtubule inhibitor agent103.  
3. PI3K/AKT/mTOR pathway. This pathway is active in 70% of the tumors. Apart 
from everolimus, promising results in clinical trials suggest pictilisib, a PI3K 
inhibitor, as a future therapeutic104 as well as an inhibitor of AKT105. 
 
2.4. Cardiotoxicity in breast cancer 
 
The incidence of cancer treatment-induced cardiotoxicity depends on the cancer 
therapy used, duration of the treatment, and the patients. Up to 48% of cancer patients 
treated with anthracyclines suffer from cardiovascular problems after the treatment. 
This percentage includes the treatment of solid tumors as breast cancer and 
hematologic cancer as Hodgkin/non-Hodgkin, lymphoma, leukemias, among others106.  
Regarding the monoclonal antibodies, Trastuzumab-induced cardiotoxicity alone 
ranges from 3% to 7%, and when administered with other chemotherapeutics, specially 
anthracyclines, affect 27% of the patients107. By inhibiting ErbB2, trastuzumab reduces 
the protection from mitochondrial damage in cardiomyocyte108. 
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An interesting retrospective cohort study evaluated on 2011 by Patnaik J, et al. 
109 shows how the leading cause of death in diagnosed breast cancer patients are the 
cardiovascular events related to chemotherapy treatment (Figure 3). 
 
Figure 3. Distribution of leading causes of deaths in diagnosed breast cancer patients over 
the years. The image is taken from Patnaik J, et al 2011. 
 
The study was a follow-up of 105 months in 63,566 women diagnosed with 
breast cancer. In the first ten years, breast cancer was the cumulative primary cause of 
death. Then cardiovascular diseases became the cumulative primary cause of death. The 
number of deaths due to other reasons also increased as years passed. According to the 
study some examples of complications are pneumonia or diabetes. The study concludes 
that older women diagnosed with breast cancer have the same probability of dying of 
cancer as of cardiovascular disease. This conclusion highlights the importance of having 
a follow-up in terms of cardiac side effects.  
 




Multiple Myeloma (MM) is considered a rare disease but is the second most 
common hematological cancer after non-Hodgkin disease. Very often MM begins with 
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a condition known as monoclonal gammopathy of undetermined significance (MGUS) 
this implies: presence of an abnormal protein antibody known as monoclonal 
immunoglobulin (M protein) at ˂3g/dl levels in the blood or urine, a small amount of 
abnormal plasma B cells in the bone marrow (less than 10%) and absence of damage in 
the target organs110. Not all the patients with MGUS developed MM, only a 1% progress 
to the active disease; some of them develop an intermediate stage between MGUS and 
MM called smoldering MM, is asymptomatic and present >3g/dl levels of M protein and 
10%-60% of plasma cells in the bone marrow111. Then a 10% of these patients will 
develop MM in the first five years. The probability is higher than MGUS patients and 
after this time, the probability decreases.  
It is believed that MGUS premalignant status came from a plasma cell that 
regained its capacity to proliferate through two possible different events. First, more 
than 50% of the MGUS and MM cells present hyperdiploid usually in the odd number 
chromosomes (3,5,7,9,11,15,19). Second, in the non-hyperdiploid chromosomes are 
present well-described translocations, t(11,14) in the gene IGH (Immunoglobulin Heavy-
Chain) and t(14,22) in the IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) that 
confers more risk to develop the disease112. But as in order tumors, multiple hits take 
part in the disease; secondary translocations plus different genetic events drive the 
clonal evolution of MGUS to MM. Each newly diagnosed patient has mutations in a large 
number of genes but among the most repeated are TP53, KRAS, NRAS, ATM, CCND1 and 
FAM46C113 and is essential not to overlook that changes in tumor microenvironment 




According to the American Cancer society in 2019 were diagnosed 32,110 of new 
MM cases: 18,130 men and 13,980 women, and about 12,960 deaths are expected to 
occur74. People diagnosed with MM are at least 65 years old, and only 1% of the cases 
are younger than 35 years old. Men are more likely to suffer the disease than women 
and some MM subtypes are up to 3 times more common in African Americans 
individuals as compare to European American114.  
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Sometimes MM does not respond to the treatment (refractory) or return after 
60 days of treatment, months or even years (relapses)115. That recurrence can be clinical, 
which implies the symptoms described in the next section or biochemical when there is 
a rise in monoclonal M proteins in serum or urine116. 
 
3.3. The common signs in MM and stages of the disease 
 
The signs are used to stage the disease and can be described with the acronym 
CRAB117: C for calcium means hypercalcemia due to malignant plasma cells grow up into 
the bones. This high concentration causes renal failure. R for renal and kidney 
dysfunction caused by the accumulation of the M protein in the urine, as well as the 
induced by the hypercalcemia; advanced MM patients required dialysis. A for anemia, 
as a malignant plasma cells, take out space in the bone marrow and disrupt the 
production of blood cells. B for bone disease, particularly painful in the back and chest. 
Calcium is removed from the bones, so they become more fragile and thinner causing 
osteoporosis that increases the chance of breakage. Furthermore, the International 
Myeloma Working Group (IMWG) in 2014, added three new criteria in case of the 
patients do not present the symptoms clearly, clonal bone marrow plasma cells greater 
than or equal to 60%, serum-free light chain (FLC) ratio greater than or equal to 100 
provided involved FLC level is 100 mg/L or higher, or more than one focal lesion on 
MRI118. 
Regarding the pathology of the disease, stages in MM can be classified using two 
different methods; the more recent and commonly used is the International Staging 
System96 which evaluates four main things: concentration of Albumin, β2 microglobulin, 
lactate dehydrogenase and genetic changes. Based on those, there are three main 
stages. Stage I, it presents low levels of those molecules. In this stage, most people do 
not know they are suffering the disease until it is more advanced. Stage II, β2 
microglobulin is a bit high but the other molecules present normal concentrations. Stage 
III, β2 microglobulin is very high, 5.5mg/L or more that indicates the disease is advanced. 
Also, albumin and lactate dehydrogenase are either elevated and high-risk of 
cytogenetic alterations.  
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3.4. Pharmacological treatment of Multiple Myeloma 
 
3.4.1. Ubiquitin proteasome system 
 
The ubiquitin-proteasome system (UPS) plays a critical multistep process in 
cellular protein homeostasis being necessary for cell physiology and survival. It is 
responsible for the degradation of unneeded or damaged proteins through proteolysis. 
The peptides resulting can be waste or recycled to produce new useful proteins. That 
implies processes as the adaptation to physiological conditions through the control of 
the proteins responsible for protein expression in response to stress. 
This system starts with the coordination of three enzymes, E1, E2, and E3 ligases 
which ubiquitinate a specific protein to be degraded by the proteasome (Figure 4).  
 
Figure 4. Overview of the Ubiquitin-Proteasome Pathway (UPP). 
Dark blue, green and light blue structures are E1, E2 and E3 enzymes, respectively. The three 
main steps are activation, when E1 enzyme forms a thioester bond with the ubiquitin molecule 
in the presence of ATP; the next step, conjugation of the activated ubiquitin to the E2 enzyme, 
and then to the E3 enzyme. E3 transfers the ubiquitin to the lysine residue in the substrate 
protein. The target ubiquitinated protein is then recognized by the 19s cap of the proteasome. 
 
The proteasome is a structure located in both places, in the cytosol, associated 
with the centrosomes, cytoskeleton and the outer surface of the endoplasmic reticulum, 
and in the nucleus along with the nucleoplasm, but not in the nucleoli. It is formed by a 
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conserved multicatalytic enzymes separated in two complexes: the 19S particle binds 
both sides end of the 20S core and its formed by the lid, responsible of selecting the 
proteins ready for degradation and performs the deubiquitylation process and the base, 
which is constituted of ATPase and non-ATPase subunits in charge of unfolded the 
proteins and translocation into the 20S core119. 
The 20S core is composed of 7 α and β subunits forming four heptameric rings. 
The outer α rings bind to both β rings and their primary function is being a gate through 
which proteins enter the proteasome. The β subunits are the proteolytic site, in three of 
the subunits rely the hydrolyzing activities that breaks the peptides bonds on the 
carboxyl site of acidic (Caspase-Like, C-L), basic (Trypsin-Like, T-L) and Chymotrypsin-Like 
(CT-L). All together complete the 26S proteasome (Figure 5).  
Figure 5. Proteasome 26S in detail 
Green structure is the lid and the base (ATPase activity), together form the 19S Complex. Dark 
blue are alpha rings and light blue beta rings. On the right, the alpha ring in detail. Pink 









• Proteasome inhibitors 
 
The use of proteasome inhibitors has revolutionized the treatment of Multiple 
Myeloma disease. To date, three agents in this class have been approved by the FDA. 
The first was Bortezomib (PS-341, Velcade)120 in 2003 which binds reversibly to the 
subunits caspase-like (β1) and chymotrypsin-like (β5), then in 2012 a second-generation 
agent Carfilzomib (PR-171, Kyprolis)121 that binds irreversibly to the chymotrypsin-like 
subunit (β5) and finally, Ixazomib (MLN9708, Ninlaro), the first oral PI that reversibly 
binds to the three subunits122. Furthermore, three second-generation proteasome 
inhibitors are currently in Phase I/II investigations: Oprozomib, Delanzomib and 
Marizomib (Supplementary Table 1) with their different pharmacological properties 
they have demonstrated a safety profile and positive results in patients resistant to 
bortezomib123–125. These PIs in doublet o triplet regime with immunomodulators and 
glucocorticoids present promising results in relapsed or refractory patients (Figure 6).  
Figure 6. Six proteasome inhibitors and their target subunit 
The yellow cross indicates at which subunit is bind each proteasome inhibitor. The color coded 
is the same as in Figure 5. 
 
As other potential targets, the immunoproteasome, ubiquitin E3 ligases, the 19S 
proteasome, and deubiquitinates in pre-clinical studies represent possible directions for 
future generation inhibitors of the ubiquitin-proteasome system in the treatment of 





Usually dexamethasone is the selected steroid for completing the combined 
treatment in multiple myeloma disease. It has been described several mechanisms in 
which the activated glucocorticoids inhibit the NFKβ pathway. In lymphocytes and 
monocytes have been proved that dexamethasone induces the transcription of the IkB 
gene that means an increase of NFKB inactive in the nucleus. However, further 
investigations describe how glucocorticoid response element (GRE) transactivation is 
entirely related to apoptosis in treated myeloma cell lines and how NFKβ activation or 
RAFTK phosphorylation are not required126. 
 
• Immunomodulators (iMiDs)  
 
Immunomodulators work by different mechanisms in the treatment of MM. 
They have an anti-angiogenic effect, anti-inflammatory, anti-proliferative and immune-
modulatory effects127. The survival success in any tumor cell is the endogenous 
tolerance offered by the immune system. Immunomodulators can activate T cells but 
only if they are previously activated by a CD3+T cell. Lenalidomide seems to be up to 
2000 times more potent inducing T-cell proliferation than thalidomide and 
pomalidomide appears more potent than lenalidomide in terms of T-cell 
stimulation128,129. Apart from modulating the immune environment, iMiDs also present 
an antiproliferative effect inhibiting the cyclin-dependent kinase pathway. Their anti-
angiogenic properties are not well established yet; some studies suggest that occurs via 
modulating some endothelial factors like VEGF, TNFα, or βFGF rather than direct 
inhibition of the endothelial cell proliferation130.  
 
3.5. Cardiotoxicity in Multiple Myeloma 
 
The three current proteasome inhibitors approved by the FDA are a promising 
treatment for multiple myeloma. Their side effects in the heart were not monitoring 
from the beginning, and studies gradually emerge reporting every new case. Some of 
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the data reveal that patients treated with the combination Bortezomib, lenalidomide 
and dexamethasone present up to 8% arrhythmias, including atrial fibrillation and 
dysregulation of QT interval and up to 4% thrombosis. Regarding Carfilzomib there is an 
interesting parallel study131 comparing two regimes Carfilzomib plus Lenalidomide, and 
Dexamethasone and Carfilzomib with Dexamethasone alone. The results showed that 
up to 6.4% of the patients treated with the first treatment and 4.1% treated with the 
second one, presented chronic heart failure; 5.9% ischemia heart disease with the first 
treatment and 4.6% in the second one; thromboembolic events in 10.2% with the first 
treatment and 6.2% in the second one and hypotension in 14.3% with the first treatment 
and 6.9% in second treatment. If Bortezomib plus Dexamethasone and Carfilzomib plus 
Dexamethasone are compared, it was found that 1.75% vs. 4.75% of the patients 
suffered from cardiac failure, respectively. Finally, Ixazomib is the newest proteasome 
inhibitor approved by the FDA, limited data are available of the cardiac effects of this 
drug until now only one case has been reported in the literature suggesting a potential 
adverse effect as other proteasome inhibitors.  
Regarding the new proteasome inhibitors, they offer new advantages over the first 
generation in terms of via of administration (oral) and it seems to have potentially less 
toxicity. As a novel therapy, it forces the researches to study in-depth and developed 
new tools to predict and mitigate any side effect in cancer patients because the high-
risk patient population remains unknown. With our study, we pretend to provide 
relevant information in the field.  
 
 
4. Complex diseases and missing heritability 
 
Susceptibility to suffer cardiotoxicity due to an oncological treatment is not 
driven by a unique gene but caused by multiple genes with a weak effect132. Even in 
cases when patients have genetic predisposition to suffer the disease, these genes have 
low penetrance and adjacent genes modified the risk. Regarding the anthracyclines-
induced cardiotoxicity up to 28 studies have examined the association between the 
genetic variants and this undesirable side-effect, finding some risk variants which could 
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contribute to the development of the disease133. Furthermore, other features present 
in the disease as age, the oxidative stress factors, response to the treatment and the 
oncological disease itself are considered as complex phenotypes that are regulated by 
the effect of genes implied in several processes at different biological levels.  
 
4.1. The missing heritability problem 
 
Part of the phenotypic variability observed in a complex trait in a population has 
a genetic origin. It is determined by genetic differences between the individuals in the 
population and the influence of the environment on them. Heritability, broadly 
speaking, is defined as the proportion of phenotypic variance explained by the genotypic 
variance, while heritability, in the strict sense is the proportion of the phenotypic 
variability due to the additive genetic component, excluding the genetic determinants 
related to epistasis and gene dominance134. In linkage analysis, the genomic regions 
associated with the variability of a complex phenotype are called quantitative trait loci 
or QTL.  
There are traits where the proportion of the phenotypic variance explained by 
the genetic component is enormous. As an example, the height of a person is explained 
by 80%-90% of the heritable genetic component135. Nevertheless, there has been 
identified several genetic variants associated with the variability in height in humans but 
together only explained 5% to 10% of the phenotypic variance. This is not a specific 
problem of the height. In general, there is a large discrepancy between the proportion 
of phenotypic variability that is believed it is due to genetic differences; and the 
percentage of this variability which could be directly attributable to the genetic variants 
previously associated with this phenotype. This discrepancy is known as missing 
heritability136,137. 
Regarding the complex diseases, two theories have been proposed to explain the 
genetic component and its influence. Initially, there was strong support for the so-called 
“common disease-common variant” hypothesis, which holds that disease susceptibility 
is explained by high allele frequencies in a concrete population138. The given examples 
were diseases as Alzheimer's or diabetes. Genome-wide association studies (GWAS) 
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were used as a powerful tool to identified genetic variants that may contribute to the 
disease; in fact, these studies enabled us to identify several QTL associated with complex 
phenotypes. However, the effect of every identified region only explained 1% to 2% of 
the phenotype variance and altogether no more than 30%139. So, GWAS studies failed 
to solve the problem of missing heritability140.  
Thus, a second hypothesis came out:  the “common disease-rare variant,” which 
argues that rare variants with relatively high penetrance in the population are the major 
contributors to common diseases141. GWAS are not adequate to detect these rare 
variants but massive sequence techniques allowed us to identify some of them which 
influence the complex phenotypes142,143. These studies proved that this new hypothesis 
is correct but still not solve the missing heritability problem. The genetic variants found 
do not explain a big part of expected heritability.  
 
4.2. Intermediate phenotypes in complex traits 
 
Any complex phenotype is a result of the effects of intermediate phenotypes; in 
other words, phenotypes that affect a lower biological level. Complex diseases as 
ischemic cardiopathy, diabetes or sporadic cancer are explained by these intermediate 
phenotypes participating in their pathogenesis. In some instances, the intermediate 
phenotypes are complex phenotypes, influenced by phenotypes from lower levels 
generating complex interacting networks between different processes at different levels 
that will determine the final phenotype, the disease. Thus, the variability of every 
intermediate phenotype influences the variability of phenotypes in the next levels and 
the final phenotype is a result of each intermediate phenotype contribution (Figure 7). 
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Figure 7. Intermediate phenotypes contribute to the pathogenesis of the complex disease 
through different levels: Systemic, organic/tissue, cellular and molecular. There are multiple 
interactions at each level and between levels. Besides, all are influenced by the genetic level 
and the environment. 
 
The strategy of dividing a disease in different intermediate phenotypes to study 
the contribution of their genetic component in the genetic component of the disease 
was used mainly in psychiatry144. Psychiatric disorders are complex diseases whose 
diagnoses are based on features challenging to measure, so it is certainly complicated 
to find genetic determinants associated with this kind of neuropsychiatric disorders. 
That is the reason why in 2003, different intermediate phenotypes, as the 
neurotransmitters, were characterized as an easy way to identify the disease association 
parameters. And it is not the only field of study addressed, in other complex diseases as 
long QT syndrome145, idiopathic hemochromatosis146, juvenile myoclonic epilepsy147 or 






4.3. Missing heritability explained by genetic determinants and 
intermediate phenotypes 
 
If we consider that complex trait is a consequence of the effect of their 
intermediate phenotypes, the genetic determinants associated with the principal 
phenotype, are contributing to the variability of this phenotype through their 
intermediate phenotypes. In this way, only the genetic determinants with a substantial 
effect on the central phenotype could be detected. For example, if we perform linkage 
analysis on a complex trait of interest, we will only identify those QTL with a robust 
active contribution in the association between these two traits. It could be possible that 
all the intermediate phenotypes that take part in the variability of a complex phenotype 
were not directly detected and related to the primary phenotype. Nevertheless, all the 
genetic determinants associated with the intermediate phenotypes will have an effect 
on the primary phenotype and those not detected could have and influence in the 
missing heritability149. 
That is the reason why we have proposed a strategy to identify a part of the 
missing heritability related to complex diseases studying the intermediate phenotypes 
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HYPOTHESIS AND GOALS 
 
Oncological drug-induced cardiotoxicity is a complex disease. The susceptibility 
and evolution of this side effect varies between patients based on the environment 
influence and their genetic background150. As a polygenic disease their variability is due 
to complex interactions on the whole organism undertaken by the intermediate 
phenotypes. On the other hand, the use of hiPSCs-CMs has revolutionized the drug 
screening field giving us a safe disease human modeling to identify the possible cardiac 
side effects of novel drugs in the heart151.  
In this work we hypothesized that part of the susceptibility to develop the 
disease could be explained by differences in intermediate phenotypes. Prove this theory 
in humans is arduous, the population is too heterogenic and their interaction with the 
environment is difficult to control and quantify152. To accomplish this problem, we work 
in a heterogenic cohort of mice genetically simplify and in controlled environmental 
conditions. Furthermore, considering that nowadays is impossible to makes a primary 
culture of human heart if we use human embryonic stem cells-derived cardiomyocytes 
instead may help us to understand and classify new oncological drugs according to their 
possible toxicity. 
To validate the first study, we assessed the drug-induced cardiotoxicity in mice 
with different genetic background, therapy regime and aging and then, trying to identify 
genetic determinants associated to this cardiotoxicity. We were interested in knowing 
to what extent the intermediate phenotype in response to treatment help to define the 
behaviour of the disease. First in the parental strains so-called F1 and FVB and then in 
the heterogenic cohort of mice generated through a backcross (BX2) which its genetic 
variability contributes to different response to treatment. To validate the second study, 
cardiomyocytes were differentiated form hiPSCs in order to work with a healthy human 
model. Different drug combinations, mimicking the first-line treatments in clinic and the 
current clinical trials in multiple myeloma, were tested to describe possible cardiotoxic 
effects as measured by contractility and voltage analysis.  
 




This works aims describe novel strategies to identified susceptibility to cardiotoxicity by 
anthracyclines and proteasome inhibitors both in combination with other compound as 




• Goal 1: To identify genetic and plasma markers of anthracycline-induced 
cardiotoxicity in patients by using intermediate phenotypes in the context of 
breast cancer. 
 
• Goal 2: Screening of the specific cardiotoxicity produced by proteasome 
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MATERIALS AND METHODS 
 
1. Animal models 
 
1.1. Mouse strains 
 
The inbred strains used in this study were:  C57BL/6J mice that were resistant to 
breast cancer153. FVB/N strain, which is susceptible to develop breast cancer154, both of 
them were collected from the Laboratorios Charles River España.  
The FVB/N-Tg(MMTVneu)202Mul/J transgenic mice (Erbb2/Neu mice, from 
now), on FVB genetic background, carry the Erbb2/Neu protooncogene under the 
expression of the LTR of the Mouse Mammary Tumor Virus (MMTV) promoter. These 
mice were collected from Jackson Laboratories and generated in the laboratory of Dr. 
Muller155. The transgene contains the cDNA wild type version of the Erbb2/Neu gene 
from rat expressed under thee MMTV promoter; the construct also contains alternative 
splicings and polyadenylation sequences from the SV40 virus that gives stability to the 
transcript. The transgene does not induce phenotypic changes in males and is expressed 
at lower levels in the mammary epithelium, salivary glands, spleen, thymus, and lungs, 
but at high levels in tumors. In contrast, in females, induces breast adenocarcinomas 
surrounded by hyperplasic mammary tissue from 4 months of age with an average of 7 
months. Besides, more than 70% of the mice develop lung metastases when older than 
eight months of age. 
Animals were kept in the Servicio de Experimentación Animal in the Universidad 
de Salamanca under specified pathogens free (SPF) conditions. During the study the 
practices were under the provisions of the European Union under the Real Decreto 
1201/2005 on October 10 at Ministerio de Agricultura, Pesca y Ganadería regarding the 
“Protección de animales utilizados para experimentación y otros fines expecíficos.” The 
project was approved by the Bioethics Committee at the Universidad de Salamanca.  
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1.2. Mouse cohort generation with phenotypic and genetic 
variability by a backcross  
 
The backcross strategy (Figure 8) aims to generate a mouse cohort with different 
behavior in a specific phenotype, cardiotoxicity induced by chemotherapy. Once the 
mice developed breast cancer, they were treated with chemotherapeutic agents under 
conditions similar to those used in clinics. The goal is to study the different cardiotoxic 
patterns in each mouse. As parental strains, we selected the resistant mouse strain to 
breast cancer C57BL/6J (F/F) and the susceptible strain FVB/NJ (B/B). After the cross, the 
offspring was genetically heterogeneous and carried an allele from each parental strain 
and were called the F1 (F/B) mice.  
The F1 mice were backcrossed with the Erbb2/Neu mice under the susceptible 
FVB/NJ genetic background. The Erbb2/Neutransgenic mice carried the transgene in 
both chromosomes in homozygous status. Thus, the F1 backcross cohort (F1BX mice 
after that) generated carried the MMTV-Erbb2/Neu transgene in all the mice. Also, each 
mouse from the backcross cohort carried a unique combination of alleles from both 
strains, in a variable proportion. In this genetic background, the genetic component from 
the FVB strain was the majority since it was the one used to generate the backcross with 
the F1 mice. FVB alleles can be either in homozygous or heterozygous status, while the 
C57 component is reduced and is always in heterozygosity when it appears.  
Figure 8. Generation of the mouse backcross cohort 
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1.3. DNA isolation and quantification 
 
DNA was phenol-chloroform extracted using tail and heart tissues previously 
frozen in liquid nitrogen and stored at -80°C. Samples were incubated with 500µl lysis 
buffer (Tris 100mM pH 8, Etilenediaminetetraacetic acid (EDTA) 5mM, SDS 0.2%, NaCl 
2mM) and 1µl of Proteinase K (100mg/µl) (Roche, #3115801001) overnight at 55˚C. The 
next day 500µl of phenol/chloroform/isoamyl alcohol (25:24:1) was added (AppliChem 
#A2493). The whole mixture was transferred to a 5PRIME Phase Lock Gel (QuantaBio 
#2302820) tubes, and after centrifugation for 5 minutes at 12000 rpm, the organic phase 
and the interphase materials are effectively trapped in or below the barrier gel, thus 
enabling complete and easy decanting or pipetting of the entire aqueous phase. This 
aqueous phase, that contains the DNA was taken into a new 1.5 mL tube (Eppendorf# 
033871) with isopropanol (Fisher Reagents #W992DM). DNA is not soluble in 
Isopropanol, so it precipitates. Again, after 5 minutes of centrifugation at 12000 rpm, 
the supernatant was removed, and the DNA pellet was washed with 70% ethanol to 
eliminate salts and was centrifuged in the same conditions. After removing the 
supernatant and allowing the residual Ethanol to be evaporated completely, DNA 
extracted was resuspended in 100µl of buffer TE (Tris 100mM pH 8, EDTA 1mM) and was 
homogenized at room temperature at least one hour before use. The concentration of 
double-stranded DNA (dsDNA) was measured at a wavelength of 260 nm by a 
microspectrophotometer (Nanodrop ND-1000) in triplicate. 
 
1.4. Detection of the MMTV-Erbb2/Neu transgene by PCR 
 
A small piece of a tail was cut by a heating system (Hot bead sterilizer, #18000-
45, F.S.T.) to get cauterization, hemostasis, and sterility at the same time and DNA was 
extracted from it (see DNA extraction protocol). The sequences of the primers were: 
oIMR0386:  5’-TTTCCTGCAGCAGCCTACGC-3’ 
oIMR0387:  5’CGGAACCCACATCAGGCC-3’ 
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The PCR program is described in the following Table 1. The size of the transgene 
was 600 pair bases (pb) and was visualized in a 1.5% agarose gel by electrophoresis. 
Table 1: PCR program for the amplification of the MMTV-Erbb2/Neu transgene 
Step Temperature Duration Notes 
1 94˚C 3 min   
2 94˚C 20 sec 
x 12 cycles                     
(-0.5˚C each cycle) 3 64˚C 30 sec 
4 72˚C 35 sec 
5 94˚C 20 sec 
x 25 cycles 6 58˚C 30 sec 
7 72˚C 35 sec 
8 72˚C 2 min   
9 10˚C   Hold  
 
 
1.5. Mouse Genotyping  
 
Briefly, tail DNA concentrations were measured by the Nanodrop ND-1000 
Spectrophotometer and by the PicoGreen double-stranded quantification method 
(Molecular Probes, Thermo Fisher Scientific Inc., Waltham, MA USA # P11495). For 
genotyping, the genome-wide scan was carried out at the Centro Nacional de 
Genotipado (CEGEN) at the Centro Nacional de Investigaciones Oncológicas (CNIO, 
Madrid, Spain). The Illumina Mouse Medium Density Linkage Panel Assay was used to 
genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes 
were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs were 
informative from the FVB and C57BL/6 mice; the average genomic distance between 
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1.6. Chemotherapy treatment in the backcross population 
 
The mice were treated with chemotherapy once they had developed breast 
cancer. Thus, we evaluated cardiotoxicity in 165 mice: the F1BX (N = 130) and in the FVB 
(N = 18) and F1 (N = 17) female mice. 
One group (N = 88) was treated with a total of 25mg/kg of doxorubicin (Pfizer) in 
five intraperitoneal injections of 5mg/kg at ten days intervals156, and another (N = 77) 
received a combined therapy of doxorubicin (Pfizer) (5 mg/kg) plus docetaxel (Sanofi 
Aventis) (25 mg/kg)157, administered intraperitoneally every ten days under isofluorane 
anesthesia. The mice received at least four cycles of therapy and a maximum of five 
cycles when the chemotherapy was well-tolerated. Once the treatment had finished, 
the progress of the mice and tumor development was assessed for two months. Then, 
necropsies were performed, and the heart and other tissues were obtained.  
 
1.7. Heart tissue processing  
 
The mouse hearts were fixed in 4% paraformaldehyde (Scharlau FO) for 24 hours 
and then were processed in an automatic system (Shandon Excelsior, Thermo). The 
subsequent samples were sectioned, embedded in paraffin, and stained with 
hematoxylin-eosin with a standard protocol or with the Masson Trichrome Goldner kit 
(Bio-Optics) to evaluate for cardiac fibrosis and cardiomyocyte area. 
 
1.8. Heart damage quantification 
 
To evaluate the histopathological damage of the heart tissue from mice following 
chemotherapy, we quantified the area of heart fibrosis and the average area of the 
cardiac fibers as pathophenotypes of CDA using the ARIOL slide scanner. These 
pathophenotypes of cardiotoxicity were quantified in both the subendocardial and the 
subepicardial zones. Five areas were randomly chosen from each zone. 
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1.9. Protein isolation and quantification from heart mice 
 
Approximately 10-15 mg of cardiac tissue previously-stored at -80˚C were 
homogenized using the FastPrep Homogenizer system (FP120, Bio 101 Thermo Savant) 
and ceramic beads (Precellys Lysing Kit CkMix, Precellys #10409) in Lysis buffer (Lysis 
Buffer 1X, Milliplex #43-040) through 2 simultaneous 10 seconds beats, 5.5 intensity 
(m/s) at 4 ˚C. The pulverized samples were incubated on ice for 20 minutes and then 
centrifuged at high speed at 4˚C, 5 minutes to allow solids not dissolved in the buffer 
formed a pellet. The supernatant was removed and filtered through 0.65µm pores, 
which is an essential step for the Luminex assay (see below). A 1:10 dilution was made, 
and protein quantification was carried out using the BCA Protein Assay test (BCA protein 
assay reagent A, 500ml, #23228, and BCA protein assay reagent B 25mL #23224), 
according to the manufacturer's instructions. Each sample was analyzed in triplicate. 
Absorbance was measured using the Ultra-Evolution TECAN and the Xfluor program at 
570nm. Data were analyzed on Excel Office 365 software, and protein concentration 
was calculated by comparison between the standard curve made with known 
concentration levels of Albumin, which cover the expected range of the samples tested 
(Thermo Fisher Albumin standard #11811345) regarding their unknown protein 
concentrations. 
 
1.10. Quantification of signaling proteins in heart samples: Luminex 
technology 
 
Quantification of signaling proteins in protein lysates of hearts of the F1BX cohort 
was performed by multiplex assays with Millipore Luminex xMAP® technology 
(Milliplex®) following the manufacturer’s instructions, and the Bioplex 200 device (BIO-
RAD), borrowed from the Biochemistry Service of the Salamanca University Hospital and 
The Proteomic Unit in our Centre. Measurements were taken from distinct samples in 
96-well plates. These multiplex assays have the advantage over ELISA that they allow 
quantifying the levels of various proteins in a single assay. They are based on the use of 
6.45 µm diameter magnetic microspheres internally stained with a mixture of two 
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fluorescent dyes, and which have a capture antibody attached to them (Figure 9). The 
levels of total ATR, pCHK1(S345), pCHK2(T68), ɤH2AX, p-P53(S15), total MDM2 and total 
P21 were quantified using the 7-plex DNA Damage/Genotoxicity Magnetic Bead Kit 
(Milliplex Map Kit #48-621MAG, Millipore), to which the buffer-compatible MAPmates 
assays were added to quantify the levels of activated caspase-3, and β-tubulin (#46-
713MAG). Another test used was the 9 Plex Multi-Pathway Magnetic Bead Kit (Milliplex 
Map Kit #48-680MAG), which included the reagents needed to quantify 
pERK1/2(T185/Y187), p-P38MAPK(T180/Y182), p-NFκB(S536), pJNK(T183/Y185), 
pAKT(S473), p-P70S6K(T412), pCREB(S133), pSTAT3(S727) and pSTAT5(Y694/699). 
Finally, we quantified the levels of TGFβ-1, TGFβ-2, and TGFβ-3 with the Milliplex MAP 
TGFβ Magnetic-Bead 3 Plex Kit (#TGFMAG64K-03, Millipore). 
 
Figure 9: Luminex technology. The assay is performed in a 96-well plate with 25µg of protein. 
Each color-coded magnetic microsphere has a specific antibody on the surface (capture 
antibody), which binds to the protein of interest (target analyte). A second antibody is added 
(detection antibody-StreptavidinPhycoerythrin SAPE), and then with the Luminex®200TM 
system is analyzed. 
 
1.11. Quantification of telomere length by QPCR 
 
DNA from heart tissue was extracted and quantified following the protocol 
previously described (see DNA isolation and quantification). QPCR was performed 
following the conditions published elsewhere158. Briefly, PCR reactions were carried out 
in a total volume of 12 µl in Twin-Tec real-time PCR plates 96 (#0030132513, Eppendorf) 
with the following reagents: 6 µl of PerfeCTa SYBR® Green SuperMix ROX (#733-1188, 
VWR) (1X) and 1.6 µl of 150 mM forward and reverse telomeric primers (5’- 
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CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3’ and 5’-
GCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-3’, respectively). Also, the acidic 
ribosomal phosphoprotein PO (36B4) gene was used to normalize the amount of DNA. 
Forward and reverse primers for the 36B4 gene were 5’- ACTGGTCTAGGACCCGAGAAG-
3’ and 5’-TCAATGGTGCCTCTGGAGATT-3’, respectively, to which 1 µl of DNA (10 ng) and 
3.4 μl double-distilled H2O were added. QPCR reactions were performed in triplicate 
following the conditions indicated. An automated thermocycler (Mastercycler ep 
Realplex2, Eppendorf) was used to carry out the PCR reactions, and data analysis was 
done using the 2-ΔΔCt method159 (see Analysis of the Results section). 
 
1.12. Total RNA isolation 
 
Total RNA from heart tissues was isolated using the QIAGEN®kit (RNeasy®, 
CAT#74104) following the manufacturer's instructions. Briefly, the heart tissues were 
disrupted and homogenized using the TissueRuptor at 4°C. The RNAs were extracted 
with a mix of buffers, followed by precipitation in ethanol, and purified using RNase-free 
columns. The RNA concentrations were determined using a spectrophotometer 
(Nanodrop) and microfluidic chips (Agilent).  
 
1.13.  cDNA synthesis from miRNA in the heart 
 
The protocol chosen was obtained from the TaqMan Advanced miRNA cDNA 
synthesis kit (Thermo Scientific #A28007) to modify and amplify the small miRNAs in the 
sample. The protocol was based on four main sections: 
 
• Poly(A) tailing reaction (55 minutes)  
 
This step extended the 3’ end with a polyadenylated (Poly A) tail to increase the 
stability and enhanced the translational process. The reagent’s cocktail for each 2µl 
sample is shown in Table 2: 
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Table 2. Poly A tailing reaction. Amount of reagent in each sample. 
Reagents x1 sample(2µl) 
10x Poly (A) Buffer 0.5 µl 
ATP 0.5 µl 
Poly (A) Enzyme 0.3 µl 
Rnase-Free Water 1.7 µl 
Total Volume 3 µl 
 
The thermocycling settings are shown in Table 3: 
Table 3. PCR program for the Poly A tailing reaction. 
Step Temperature Duration 
Polyadenylation 37˚C 45 min 
Stop reaction 65˚C 10 min 
Hold 4˚C Hold 
 
After this step, the ligation reaction was processed immediately. 
 
• Ligation reaction (60 minutes) 
 
Ligation reagents were thawed on ice during the Poly (A) tailing reaction was run 
in the thermocycler. In this step, the 5’ ends of the miRNA were lengthened by an 
adaptor ligation. This step helped to enhance the expression profiles and the 
reproducibility between samples. The cocktail of reagents was prepared based on the 
following Table 4:  
Table 4. Amount of reagents per sample for each ligation reaction. 
Reagents x 1 sample (2µl) 
5x DNA Ligase Buffer 3 µl 
50% PEG 8000 4.5 µl 
25% Ligation Adaptor 0.6 µl 
RNA Ligase 1.5 µl 
RNase-Free Water 0.4 µl 
Total Volume 10 µl 
 
Polyethylene glycol (PEG) is extremely viscous, essential steps when performing 
this part are: working with the PEG at room temperature, when aspirating wait for 10 
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seconds before removing the pipette from the tube ,and, when dispensing in the cocktail 
tube keep the plunger 10 seconds more than needed, in other to allow all the PEG to be 
entirely dispensed.  
The tube was incubated with the following settings (Table 5): 
Table 5. PCR program for the ligation reaction. 
Step Temperature Duration 
Ligation 16˚C 60 min 
Hold 4˚C Hold 
 
After the ligation part, the reverse transcription process was performed 
immediately. 
 
• Reverse transcription reaction (20 minutes)  
 
In this section, cDNAs were obtained from the modified miRNAs. The reaction 
mix was prepared based on the following table: 
Table 6. Amount of reagent in each sample for the ligation reaction. 
Reagents x 1 sample (2µl) 
5x RT Buffer 6 µl 
dNTPs Mix (25mM) 1.2 µl 
20x Universal RT Primer 1.5 µl 
10x RT Enzyme Mix 3 µl 
RNase-free water 3.3 µl 
Total Volume 15 µl 
 
And then was incubated following the next settings: 
 
Table 7: PCR program for the reverse transcription reaction. 
Step Temperature Duration 
Reverse Transcription 42˚C 15 min 
Stop reaction 85˚C 5 min 
Hold 4˚C Hold 
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At this point, the samples could be stored at -20˚C or proceeded to the 
amplification step. 
• miRs amplification reaction (30 min) 
 
This step was performed to increase the concentration of miRNAs 
homogeneously. The reaction mix is shown in the following Table 8: 
Table 8: Amplification reaction. Reagent for each sample for this step. 
Reagents x 1 sample (2µl) 
2x miR-Amp Master Mix 25 µl 
20x miR-Amp Primer Mix 2.5 µl 
RNase-Free Water 17.5 µl 
Total Volume 45 µl 
 
The thermocycler program was:  
Table 9: PCR program for the amplification reaction 
Step Temperature Duration Cycles 
Enzyme Activation 95˚C 5 min 1 
Denature 95˚C 3 min 14 
Anneal 60˚C 30 min 14 
Stop Reaction 99˚C 10 min 1 
Hold 4˚C Hold 1 
 
At this point, the samples were stored at -20˚C. 
 
1.14. miRNAs quantification by QPCR in heart tissue 
 
The miRNAs were quantified by Fluidigm BioMark HD technology and screened 
in 96 Dynamic arrays (96-96 Dynamic Array IFC for Genotyping #BMK-M-96.96 GT) 
(Figure 10). This tool allows us to perform 9,216 reactions and test 96 samples and 
probes simultaneously (Table 10). For the reaction, 1µl of each sample and 0.49µl of the 
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master mix were required to complete the assay. Samples were loaded in triplicates. 
The reaction occurred in the middle of the chip.  
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Table 10. List of the miRNAs studied. First, the name of the miRNA, then the TaqMan’s probes 
name and finally the catalog number. In probes, hsa indicates the probes recognizes the homo 
sapiens sequence, but the mouse sequences for these miRNAs are the same. 
miRNA Probes ID 
miR-21a-5p hsa-miR-21a-5p 477975_mir 
let-7a-5p hsa-let-7a-5p 478575_mir 




let-7i-5p hsa-let-7i-5p 478375_mir 




let-7b-5p hsa-let-7b-5p 478576_mir 
let-7g-5p hsa-let-7g-5p 478580_mir 
miR-374-5p hsa-miR-374b-5p 478389_mir 
hsa-miR-497-5p hsa-miR-497-5p 478138_mir 
miR-210-3p hsa-miR-210-3p 477970_mir 
miR-100 hsa-miR-100-5p 478224_mir 
miR-130a hsa-miR-130a-3p 477851_mir 




miR-29b hsa-miR-29b-3p 478369_mir 








miR-451 hsa-miR-451a 478107_mir 
miR-361-5p hsa-miR-361-5p 478056_mir 
 
The qPCR program used was: 50 °C (2 min), 70 °C (30 min) and 25 °C (10 min), 
followed by 50 °C (2 min) and 96.5 °C (10 min) for 40 cycles and then  96 °C (15 s) and 
60 °C (1 min). Data were analyzed, and the cycle threshold (Ct) values were determined 

































Goal 1. To identify genetic and plasma markers of anthracycline-induced 
cardiotoxicity in patients by using intermediate phenotypes in the context of 
breast cancer 
 
Cardiotoxicity due to chemotherapy is a common side effect that can be very 
grave and can modify the continuity of chemotherapy treatment160,161. Nowadays the 
cardio-oncology field try to predict the possible cardiac effects of every new treatment 
before being given into the clinical and also elucidate the susceptibility of each patient 
to suffer CDA which is very variable condition among the oncological patients162,163. 
Animal models and the novel human in vitro studies with the hiPSC-CMs are being used 
actively to reach this purpose increasingly tangible, the results that are being achieved 
are very close to what happens in the clinic164. Luckily in the future its reliability will be 
successfully corroborated in patients.  
In the first part of the work there has been a great deal of effort to identify those 
patients susceptible to developing CDA using genetic markers133 and the identification 
of plasma biomarkers165 the so-called subphenotypes. As previously described along this 
work, susceptibility to chronic CDA has a significant genetic component, and as a 
complex disease or complex trait, indicates polygenic inheritance166. Moreover, the 
genetic component of complex characters is difficult to identify, and there is a much 
discrepancy between the proportion of phenotypic variance expected to be explained 
by genetic influences, known as the "expected heritability," and the heritability 
explained by the DNA Sequencing Variants (DSVs) identified. This difference is known as 
the "missing heritability"137. Thus, CDA, as a complex trait, has an unknown component 
of missing heritability and identify most of the genetic component is challenging. 
Complex traits are influenced in their pathogenesis by a multitude of 
subphenotypes of lower rank. These subphenotypes, in turn, can be, to a greater or 
lesser extent, complex phenotypes. For example, myocardial infarction is a disease of 
complex origin whose susceptibility is determined by subphenotypes such as 
hypertension, hypercholesterolemia, or susceptibility to tobacco among others. All of 
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these subphenotypes are also complex traits influenced by lower rank subphenotypes. 
Below this multidirectional network of subphenotypes, there are molecular 
subphenotypes on which the genetic determinants act149. The use of subphenotypes to 
identify a part of the genetic component of complex traits has been previously proposed 
in the field of psychiatry144 and later on applied to other areas149. We propose that part 
of the genetic component of the "missing heritability" could be explained by the QTLs 
associated with subphenotypes that participate in the pathogenesis of the complex trait. 
These QTLs linked to subphenotypes would not be strong enough to be detected by 
linkage analysis at the complex trait level. Thus, we suggest that the identification of 
QTLs associated with essential subphenotypes in the pathogenesis of a complex trait 
could be used to identify a part of the "missing heritability"149. 
Here, we have identified a part of the genetic component linked to molecular 
subphenotypes associated with CDA. This genetic component helps to identify a part of 
the genetic elements associated with CDA susceptibility itself. To identify putative 
molecular subphenotypes of CDA, we considered that anthracyclines exert their toxicity 
through DNA damage. Thus, CDA subphenotypes would be molecular pathways involved 
in DNA damage responses  such as AKT167 or ɤH2AX168 related to protection and 
repairing of the DNA;  molecules implicated in cell cycle arresting as chk1169 and chk2170 
which are activated by genome instability and DNA damage; cell death through 
apoptosis mechanisms leading by MDM2, p53 and Caspase-3171  and p21 which is also 
related to cellular senescence and cycle arrest172–174.  
But they are not the only, we also considered protein expression levels  in 
intracellular signaling pathways related to several processes as cardiac hypertrophy 
where mechanical overload comprises the expression of signal-regulated kinases 
ERK1/2175, JNK176 , P38 MAPK177,178,NFƘβ179, AKT167; STAT3 with a pivotal role 
upregulating genes related to heart protection, cardiac stress adaptor and pathological 
remodeling180; and p70S6K as part of the PI3K pathway, involved in cell death, fate and 
survival181 among others182. Also, we hypothesized that other CDA subphenotypes could 
be molecules implicated in heart diseases and cardiotoxicity such as miRNAs183 some of 
them tissue based-specific and recognized as a potential circulation biomarker in 
humans due to its stability and resistance to RNAase degradation184; and telomere which 
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length may be a predictor of cardiac events so because its deterioration is associated 
with cell ageing and oxidative stress, one of the common mechanism in DOX-induced 
cardiovascular diseases185, although in the end was not correlated with damage 
response in our study.  
Multiple regression models have allowed us to decipher which of these 
molecular subphenotypes determined in the myocardium of mice would have higher 
explanatory power on the phenotypic variability of the CDA. Then, we determined to 
which extent the QTLs associated with these molecular subphenotypes could help to 
explain chronic CDA. Indeed, QTLs linked to myocardium levels of p70S6K(pT412), JNK 
(pT183/pY185), pCREB(S133), or ɤH2AX(Ser139) increased the phenotypic variability 
explained that is associated with heart damage in mice treated with doxorubicin 
(Figure12 and Figure13).  
Transferred to patients, allelic forms of the RPS6KB1, which encodes for p70S6K 
protein, CREB, and TUBB genes, also were associated with CDA (Figure15). We found 
p70S6K associated with CDA in four cohorts of different characteristics, two of patient 
ones and two of mice. This fact highlights the putative importance of allelic forms of 
p70S6K in the CDA susceptibility and pathogeny, and also in heart physiology. Indeed, it 
has been recently reported that after evaluating 65 protein kinases by an ex vivo test, 
the one that best predicted cardiotoxicity by these TK inhibitors was p70S6K8, and also 
other drugs, including doxorubicin186. Also, expression of RPS6KB1 gene resulted in a 
shortened action potential duration, and a shortened duration of the Ca+2 and 
contractility transients8. The protective heart effect of p70S6K has been suggested 
because its blocking has been associated with a greater area of necrosis in myocardial 
infarction models187. Also, p70S6K has been directly associated with heart fibrosis181 and 
heart diseases188,189. Based on that It might be interesting in future experiments to test 
the expression levels of this protein in other oncological treatments which also have 
reported cardiotoxic events to confirm if they follow the same expression patterns.  
Another attempt to identify patients susceptible to CDA has been through the 
determination of plasma biomarkers. Multiple biomarkers have been proposed, but 
there is not a good one that can adequately define the risk of CDA165. In this study, we 
have proposed that the quantification of molecules in plasma, whose levels in 
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myocardium were associated with cardiac damage in the backcross mice, could serve as 
plasma biomarkers of CDA. Indeed, high levels of oxidized DNA have been described in 
both the serum and myocardium of patients with heart failure190. Here, we observed an 
association between the plasma levels of some of these molecular subphenotypes 
associated with histopathological heart damage in mice and the degree of functional 
deterioration in humans by CMR (Table 2). In agreement with this, other studies have 
found a correlation between pathological damage and functional deterioration of the 




Goal 2: Screening of the specific cardiotoxicity produced by proteasome 
inhibitors and their combinations using hiPSCs-CMs in the context of 
multiple myeloma. 
 
In the second section of the PhD thesis project are shown preliminary results of 
a small project developed through the use of hiPSC-CMs. The aim was performed a 
description of the responsiveness in terms of contractility and voltage of the 
cardiomyocytes in the presence of proteasome inhibitors and their combination therapy 
with immunomodulators and Dexamethasone.  These compounds have revolutionized 
the treatment in Multiple Myeloma disease as first-line therapy and for relapsed/ 
refractory disease, but various clinical studies have started to document cardio toxic 
events in patients192,193. There is an added complication, the median diagnostic age of 
MM patients is around 70 years and at this diagnostic time, some of them present 
cardiovascular diseases or risk factors to develop them194. What makes this preliminary 
study attractive is the description in a human in vitro model the direct effect of the MM 
treatment in cardiomyocytes and being able to transfer this information to the clinic. 
Ideally in the future could contribute to distinguish between the cardiac pathology that 
already present some of the patients and the cardiotoxicity produced by the PI itself. As 
a last step being able to design personalized medicine to avoid this adverse side effects 
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in no-cardiac patients and improve the life quality in patients suffering from any cardiac 
complication.  
After verifying the treatment efficiency of every drug combination on the 
Multiple Myeloma cell lines (always mimicking the clinic) was reproduced exactly the 
same treatment pattern in the human cardiomyocytes (hiPSC-CMs). These type of 
studies looks for any abnormalities in the action potential duration or contraction195,196. 
In our results there is a correlation between the voltage and the contractility values. We 
did not appreciate any indication of pro-arrythmia patterns as expected in 
Bortezomib197 and Carfilzomib131 which would have shown as an increase in the 
triangulation index198. By contrast at higher concentration levels, the effect on the 
cardiomyocytes was fulminant, we did not detect presence of cardiac activity at any PIs 
combination. This behavior is also found in their analogs Oprozomib and Delanzomib in 
monotherapy.  
Regarding the voltage analysis, the triangulation index, the gold pro-arrythmia 
marker is low in some of the PIs such as Marizomib and all its treatment regime in which 
the values were stable but a bit low or Ixazomib and its combinations with 
Dexamethasone and Lenalidomide the values dropped unexpectedly. The explanation 
could be lower time in the cycle length (CL) consequence of action potentials which 
occur earlier than expected199.  
As promising exceptions: 1) Delanzomib in combination with Dexamethasone 
and Lenalidomide seems to be very well tolerated by cardiac cells. In the contractility 
and voltage analysis did not present any irregularity. These results fit with a Phase I/II 
study published in 2017 by Vogl DT, et al. 123 in which is described a limited cardiac toxic 
effect of this combination. In an attempt to explain the differences in response between 
Delanzomib alone and in combination was performed a proteasome activity assay that 
discarded the hypothesis that the three compounds were competing for the binding site. 
On the other hand, the option that Dexamethasone could be producing its therapeutic 
anti-inflammatory effect200 and cushioning the toxic effect is not valid since our 
experiments are developed in an in vitro model, so there must be implied some 
surrounding mechanisms. As described in the literature, the glucocorticoid signaling in 
the heart is mediated by the glucocorticoid receptor (GR) and the mineralocorticoid 
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receptor (MR); both turnovers are regulated by the ubiquitin proteasome system and 
studies with the proteasome inhibitor MG132201 showed how blocking the proteasome 
activity in the cells was translated in an increased on these two receptors. An increase 
in the glucocorticoid signaling due to GR has been described as beneficial for inhibiting 
cell death in DOX-induced cardiotoxicity202 and improving the contractility 
performance203 so, this could be an hypothesis on why the combination Delanzomib plus 
Dexamethasone and Lenalidomide did not produce an effect in the heart. This 
hypothesis has not being applied for explaining the rest of the PIs effects, although it is 
true, that long-term high-dose glucocorticoids have been related to negative effect such 
as abnormal conduction properties204. By contrast an excessive increase in MR 
activation in the heart has been related to inflammation leading to hypertrophy and 
fibrosis205. Studies that will demonstrate Dexamethasone binds more actively to this 
receptor instead of GR would explain the toxicity of certain drug combinations. 
Furthermore, in future experiments could be interesting test the proteasome activity in 
the hiPSCs-CMs and MM cell lines but only under the effect of Dexamethasone and 
Lenalidomide alone and see the effect on their viability without the PI influence.  
2) Marizomib is presented as promising drug with high target effect on U266B1 cell line 
and no effect on cardiomyocytes. There are several clinical trials evaluating this 
compound206,207 but briefings providing to date does not report cardiotoxic events. Also 
it is brain penetrant208 so open more treatment options to oncological patients 
especially those with neurological affections.  
These findings, although promising, are only preliminary results and need to be 












































Our studies in a backcross mice population show that genetic determinants and 
intermediate phenotypes can explain the susceptibility to suffer cardiotoxicity due to 
anthracyclines. 
Furthermore, the use of hiPSCs-CMs can be tested new compounds to predict 





The genetic background profoundly influences cardiotoxicity due to chemotherapy with 
doxorubicin and combined treatment with doxorubicin plus docetaxel. In this work, we 
have described part of the polygenic component and the intermediate phenotypes that 
explained part of the variability of this response in a model of genetic heterogeneity at 
the cardiac level. 
Second: 
We have proved that our strategy could help to identify susceptibility to CDA also in two 
different cohorts of patients, one diagnosed with breast cancer and other pediatric.  
Third:  
Through the use of hiPSCs, we have described how the combination with delanzomib 
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Nuevas estrategias para la identificación de la susceptibilidad a la 





Antecedentes: La cardiotoxicidad debida a antraciclinas (CDA) es un problema frecuente 
en los pacientes oncológicos que limita el tratamiento quimioterapéutico y tiene 
repercusiones en la prognosis de la enfermedad. Además, la CDA a largo plazo tiene un 
impacto en la calidad de vida de los pacientes160,161,209. Las antraciclinas producen 
necrosis aguda y apoptosis en los cardiomiocitos causando fibrosis miocárdica y daño 
crónico funcional llegando, en ocasiones, al fallo cardiaco210,211. El grado de CDA crónica 
depende de múltiples factores entre ellos la dosis de fármaco, edad, género, 
enfermedades cardiacas previas y el tratamiento combinado con otras drogas, como los 
taxanos entre otros162,163. Además, debido a la dificultad de identificar pacientes 
susceptibles a desarrollar CDA crónica, se ha puesto mucho esfuerzo en tratar de 
identificar biomarcadores en plasma. Sin embargo, ensayos clínicos recientes  no han 
demostrado hasta ahora que los biomarcadores sean una herramienta útil para la 
predicción de CDA en pacientes oncologicos165,212. Lo mismo ocurre con los marcadores 
genéticos, a día de hoy hay varias publicaciones que proponen candidatos para predecir 
la susceptibilidad a desarrollar cardiotoxicidad debido a quimioterapia133 pero ninguna 
definitiva. CDA se comporta como una enfermedad de rasgo complejo con un 
componente poligénico166. Sin embargo, el problema de los rasgos complejos es cómo 
mejorar la identificación de su influencia genética. La proporción de variabilidad 
fenotípica explicada por el componente genético se conoce como heredabilidad. Las 
variantes genéticas identificadas asociadas con las enfermedades de rasgo complejo 
contribuyen en un 10-20% de la variabilidad genética atribuible a la genética149. El resto 
es considerado como heredabilidad perdida y sus causas e identificación son un tema 
de debate136,213. Además, los rasgos complejos son consecuencia de una serie de 
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fenotipos menores que participan en su fisiopatología y patogenia, y que se denominan 
subfenotipos, fenotipos intermedios o endofenotipos144. 
Hipótesis y Objetivos: En la primera parte de este estudio propusimos que diferencias 
en la longitud telomérica, así como diferentes niveles de expresión de miRNAs y 
proteínas implicadas en diferentes rutas de señalización podrían participar en la 
susceptibilidad a la CDA y se asociarían al daño histopatológico que se produce en la 
misma. Por tanto, serían subfenotipos moleculares de la CDA. Aquí, hipotetizamos que 
los genes que determinan dichos subfenotipos moleculares podrían contribuir a la 
heredabilidad perdida de la CDA; y formas alélicas de esos genes podrían ayudar a 
identificar a los pacientes susceptibles a la misma149. Además, pensamos que esos 
subfenotipos moleculares determinados en plasma, podrían servir como biomarcadores 
de la CDA en pacientes. 
En una segunda parte de este trabajo de tesis doctoral, llevamos a cabo un estudio 
preliminar con el fin de predecir la susceptibilidad a la cardiotoxicidad in vitro de los 
inhibidores del proteasoma solos y en combinación con inmunomoduladores y 
glucocorticoides, por ser los fármacos con los que habitualmente se utilizan en la clínica. 
El estudio se llevó a cabo en cardiomiocitos humanos derivados de células 
pluripotenciales inducidas (hiPSCs-CMs). En cuanto a las combinaciones elegidas, las 
determinamos en base a las establecidas en la clínica o en los ensayos clínicos que se 
desarrollan actualmente123,125. En ambos estudios el objetivo fue ser capaces de 
identificar pacientes susceptibles a desarrollar cardiotoxicidad debido a la quimioterapia 
con estos fármacos. 
Pacientes, material y métodos: Generamos una cohorte de 130 ratones genéticamente 
heterogénea a través de un retrocruce o backcross. Los ratones fueron tratados con 
doxorrubicina o doxorrubicina más docetaxel, una vez desarrollaron cáncer de mama157. 
El grado de daño histopatológico después de la quimioterapia fue evaluado mediante la 
cuantificación de la fibrosis cardiaca y el grosor de los cardiomiocitos. Cuantificamos en 
el miocardio los niveles de una serie de proteínas que participan las vías de respuesta a 
la genotoxicidad y de las rutas de señalización mediante Luminex; así como los niveles 
de miRNAs y la longitud telomérica por QPCR. Después, evaluamos su asociación con el 
daño cardiaco histopatológico. Después se evaluó si formas alélicas de los genes que 
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codifican las proteínas asociadas con CDA (subfenotipos) en ratones, se asociaron con 
CDA en dos cohortes de pacientes tratados con antraciclinas, una formada por pacientes 
pediátricos, con diferentes tipos tumorales, y la otra por pacientes adultos tratadas de 
cáncer de mama. Además, esas moléculas fueron cuantificadas en plasma en pacientes 
cuyo grado de CDA fue medido por resonancia magnética cardiaca (cRMN).  
En la segunda parte del estudio, se evaluó la cardiotoxicidad in vitro de seis inhibidores 
del proteosoma: bortezomib, carfilzomib, ixazomib, oprozomib, delanzomib y 
marizomib; y su combinación con dos inmunomoduladores: lenalidomida y 
pomalidomida; y un glucocorticoide, Dexametasona. La elección de las concentraciones 
se basó en los valores de IC50 y Cmax de los fármacos; y las combinaciones de los 
fármacos se establecieron en función de los tratamientos que se llevan a cabo en la 
clínica o ensayos clínicos. La cardiotoxicidad in vitro se evaluó con la determinación de 
los cambios en la contractilidad y el voltaje mediante el sistema de detección IC200 (Vala 
Sciences, California, USA)59. 
Resultados: como ocurre en humanos, los ratones desarrollaron más CDA con la edad y 
con la terapia combinada. Se encontraron diferencias de CDA según su fondo genético. 
Identificamos 16 moléculas cuyos niveles de miocardio correlacionaron con daño 
histopatológico de la CDA. El análisis multivariante demostró que las moléculas con más 
implicación en el daño cardiaco fueron p70S6K(pT412), γH2AX(S139), 
P38MAPK(pT180/pY182), CREB(S133) y miRLet7b_5p. En concordancia con la naturaleza 
poligénica de la CDA, identificamos 80 loci de carácter cuantitativo (QTLs) ligados a la 
CDA. Entre ellos, como prueba de concepto, elegimos un QTL localizado en el 
cromosoma 4 (QTL-Chr.4) y otro en el cromosoma 11 (QTL-Chr.11) que se asociaron con 
daño cardiaco en diferentes condiciones. Los QTL ligados a los niveles en el miocardio 
de p70S6K(pT412), γH2AX(S139), y JNK(pT183/pY185) mejoraron la variabilidad 
fenotípica de la fibrosis cardiaca explicada por el QT-Chr.4 y QTL-Chr.11 en ratón. Los 
genotipos de formas alélicas de los genes RPSKB1, que codifica para P70S6K, CREB5 y β-
TUBULIN-6 se asociaron con susceptibilidad a la CDA en pacientes. Además, la 
cuantificación en plasma de pacientes de las proteínas relacionadas con CDA en ratón, 




En la segunda parte del estudio, los resultados obtenidos permitieron clasificar a los 
inhibidores del proteasoma en tres grupos: primero los inhibidores de proteasoma 
cardiotóxicos que incluyen bortezomib y carfilzomib, que a altas concentraciones tenían 
un efecto fulminante en los cardios deteniendo su actividad; segundo, los inhibidores 
de proteasoma no cardiotóxicos: oprozomib, ixazomib y marizomib; y tercero, y más 
interesante, la combinación de delanzomib en combinación con inmunomoduladores y 
dexamethasona, que parece tener un efecto cardioprotector sobre la toxicidad 
producida por delanzomib en monoterapia. Esta prometedora combinación está 
actualmente en ensayos clínicos, pero desconocemos si en pacientes se está observando 
el mismo efecto cardioprotector observado in vitro.  
Conclusiones: Nuestra estrategia puede servir para descubrir marcadores genéticos y 
de plasma de la CDA que podría ayudar a identificar pacientes más susceptibles de sufrir 
esta condición. Ello podría también ayudar a elegir tratamientos de quimioterapia y 
ajustar la dosis de forma más individualizada. La identificación del componente genético 
asociado a los niveles de proteínas en el miocardio asociadas con daño histopatológico 
después de la quimioterapia en una cohorte de ratón heterogénea ayudó identificar de 
parte del componente genético de la denominada “heredabilidad perdida”, en ratones 
y, probablemente, en humanos. Además, la cuantificación de esas moléculas en el 
plasma de pacientes podría servir como biomarcadores de CDA. La identificación de 
factores genéticos y moleculares responsables del incremento en el riesgo de CDA 
podría contribuir a predecir y prevenir el CDA.  
Además, el uso de hiPSC-CMs podría ser una herramienta prometedora para estudiar la 
la susceptibilidad de los pacientes a la cardiotoxicidad por drogas oncológicas214. En este 
estudio, hemos sido capaces de clasificar los inhibidores del proteasoma en tres grupos: 
cardiotóxicos, no cardiotóxicos y –Delanzomib, cuyo efecto cardiotóxico se amortiguó 
con el tratamiento combinado.   
Implicaciones traslacionales: Identificar aquellos pacientes que desarrollarán CDA es 
una tarea difícil. Aquí proponemos una estrategia para identificar marcadores genéticos 
y biomarcadores en plasma para ayudar a identificar esos pacientes.   
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En la segunda parte de nuestro estudio, a través de la descripción de los efectos los 
inhibidores de proteasoma en un modelo humano in vitro, tratar de predecir la posible 
cardiotoxicidad en pacientes de MM. Incluso en aquellos fármacos que aún no han sido 






























1.1. Susceptibilidad a la cardiotoxicidad 
 
La cardiotoxicidad debida a la quimioterapia es un problema grave en pacientes 
oncológicos. Es la principal causa de morbilidad y mortalidad a largo plazo entre los 
supervivientes de cáncer1. 
En cuanto a la CDA, aun hoy, no se puede identificar quién va a desarrollar 
cardiotoxicidad bajo un mismo régimen de tratamiento con antraciclinas. La 
susceptibilidad individual a la cardiotoxicidad es una enfermedad de rasgo complejo, 
consecuencia de interacciones entre factores genéticos y medioambientales. Además, 
se necesitan identificar nuevos biomarcadores que ayuden a predecir individuos 
potencialmente susceptibles de desarrollar cardiotoxicidad. La presencia de niveles 
elevados de ciertas moléculas se podría utilizar detectar la patología cardiaca en fases 
tempranas de la enfermedad de manera más específica. Esta sección de la introducción 
se centra en aportar información sobre los biomarcadores genéticos y cardiacos que 
podrían ayudar a predecir eventos cardiotóxicos en pacientes oncológicos.  
 
1.1.1. Predicción de la cardiotoxicidad mediante factores genéticos 
 
 Esta aproximación permite identificar marcadores tempranos de cardiotoxicidad 
a través de potenciales variantes genéticas que podrían contribuir a predecir la 
cardiotoxicidad antes de empezar el tratamiento y desarrollar agentes 





• Tratamiento quimioterapéutico: antraciclinas 
 
Actualmente, hay identificados varios SNPs directamente implicados en la 
cardiotoxicidad por antraciclinas. La mayoría están relacionados con daño al ADN, estrés 
oxidativo, metabolismo del hierro, transportadores de las antraciclinas o disfunción del 
sarcómero en la célula cardiaca. Algunos ejemplos podrían ser, el gene RPS6KB 
encargado de codificar la proteína p70s6k y MAP4K2, ambas implicadas en la ruta de las 
MAPK8 o más concretamente en pacientes pediátricos el gen (GPR)35 (rs12468485) 
relacionado con decremento de la actividad celular y estrés oxidativo después  del 
tratamiento con quimioterapia12.  
 
• Tratamiento con inhibidores del proteosoma 
 
 No hay muchos estudios centrados en este campo, aunque cada vez despierta 
más interés. Caben destacar dos muy interesantes, relacionados con el inhibidor del 
proteasoma de primera generación, Bortezomib, y el de segunda generación, 
Carfilzomib. En ambos casos, se comprobó que genes implicados en la supervivencia 
celular y la apoptosis son los responsables de la susceptibilidad a desarrollar 
cardiotoxicidad con estos tratamientos. El incremento en la activación del factor de 
transcripción NFƘβ se relacionó, en ambos casos, con cardiotoxicidad14,15. En el caso 
específico del Carfilzomib cardiotoxicidad estaría relacionada con un desequilibrio en la 
expresión de genes implicados en la expresión del factor natriurético tipo B (BNP) y el 
complejo mayor de histocompatibilidad (MHC)15.  
 
1.1.2.  Predicción mediante biomarcadores 
 
 Existe un creciente interés en la identificación de biomarcadores útiles a la hora 
de detectar cardiotoxicidad de forma temprana, para predecir el riesgo de sufrirla y para 
identificar pacientes susceptibles a sufrir de cardiotoxicidad tardía; esto últimos en 
general se trata de largos supervivientes de la enfermedad oncológica. La explicación es 
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que son una alternativa rápida ya que mediante un análisis de sangre rutinario se 
podrían detectar16.  
 Algunos de los biomarcadores actualmente aprobados en clínica son la troponina 
T20, el péptido natriurético de tipo B (BNP)215, la porción N-terminal del pro-péptido 
natriurético de tipo B (NT-proBNP)216 y miRNAs como miR-1183 o miR-21217 .  
 
1.2.  Clasificación de la cardiotoxicidad por fármacos 
 
Durante más de una década los agentes quimioterapicos causantes de 
cardiotoxicidad han sido divididos en dos grupos principales40. Los de tipo I son fármacos 
que provocan daño irreversible en el corazón, debido a su acumulación progresiva a 
medida que transcurren las dosis. Ejemplos de este tipo son la doxorrubicina, docetaxel 
o la Ciclosporina Los de tipo II o de cardiotoxicidad reversible incluyen anticuerpos 
monoclonales como trastuzumab o sunitinib, en este caso la cardiotoxicidad no es dosis-
dependiente41. De acuerdo con un estudio reciente, esta clasificación no sería muy 
acertada y propone que lo correcto sería establecer una clasificación basada en los 
mecanismos de acción y patrones de cardiotoxicidad43.  
 
1.3.  Herramientas de diagnóstico de la cardiotoxicidad 
 
En los pacientes con cáncer de mama mayores de 65 años, las enfermedades 
cardiovasculares son la primera causa de muerte46. Esto se debe a dos factores 
fundamentales: el primero, el impacto directo de los tratamientos oncológicos sobre el 
sistema cardiovascular y, segundo, a la falta monitorización para prevenir daño cardiaco, 
la cual nunca se lleva a cabo hasta que aparecen los primeros síntomas. Además, varios 
estudios sugieren que una vez aparecido el daño cardiaco, particularmente en el 
tratamiento con antraciclinas, la recuperación de la función de la fracción de eyección 
del ventrículo izquierdo ocurre solo en un porcentaje muy bajo de los pacientes47. Este 
escenario hostil hace que la Cardio-oncología emerja como uno de los campos con 
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mayor interés futuro dentro de la Cardiología e, indirectamente, de la Oncología. A día 
de hoy, la estrategia llevada a cabo por los cardiólogos es la prevención16.  
Dentro de las técnicas de imagen utilizadas para llevar a cabo esta prevención 
encontramos el ecocardiograma, global longitudinal strain (GLS), ventriculografía 
nuclear isotópica (MUGA) y la resonancia magnética cardiaca (CMR).  
 
1.4. Test en cardiomiocitos humanos derivados de células 
pluripotenciales inducidas (hiPSCs-CMs) 
 
1.4.1 Medicina personalizada y screening de drogas. 
 
El descubrimiento de las células  madre pluripotenciales inducidas ha abierto 
nuevas opciones para testar en un modelo celular la toxicidad de nuevos fármacos y 
permitir a las compañías farmacéuticas moverse de forma segura desde el laboratorio 
hasta los ensayos clínicos58. Uno de los beneficios de utilizar esta tecnología es que estas 
células se pueden generar in vitro de manera ilimitada y recapitularían la cardiotoxicidad 
que se produciría en el corazón de los individuos de los que derivan las IPs218. 
Sin embargo, existen limitaciones a la hora de utilizar los cardiomiocitos 
derivados de las IPs. Son cardiomiocitos inmaduros a nivel funcional, el cultivo celular es 
homogéneo y carecen de estructura 3D60; pero, a día de hoy, son la tecnología más 
adecuada para estudiar enfermedades cardiacas en un modelo que recapitularía mejor 
la patología del paciente donante de las IPs. Por ello su uso es muy interesante para 
llevar a cabo una medicina más personalizada en estadios tempranos en la detección de 
cardiotoxicidad, así como para evaluar la posible cardiotoxicidad de nuevos fármacos 
antes de su evaluación en pacientes y su uso clínico. 
En el caso de las antraciclinas, existen varios grupos de investigación que centran 
su atención en estos compuestos, pudiéndose establecer estudios comparativos de la 
cardiotoxicidad entre familias de fármacos. Así, se describe, por ejemplo, como el 
Trastuzumab65 provoca un defecto en la contractilidad de las hiPSCs-CMs sin que haya 
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muerte celular, mientras que las antraciclinas afectan a seriamente la viabilidad de las 
células mediante procesos de apoptosis.  
Si hablamos de inhibidores del proteasoma (PIs) y sus combinaciones, los tres 
fármacos actualmente aprobados por la FDA, Bortezomib, Carfilzomib e Ixazomib han 
registrado diferentes grados de cardiotoxicidad en la clínica71. Además, se encuentran 
en ensayo clínico dos análogos a los anteriores (Oprozomib y Delanzomib) y, uno nuevo, 
el Marizomib, de los cuales aún se necesita dilucidar si provocan cardiotoxicidad. La 
opción de testar estos fármacos en hiPSCs-CMs, como se ha llevado a cabo en este 
trabajo, nos parece una excelente alternativa para a obtener datos preliminares sobre 
posibles efectos cardiacos adversos.  
 
2. Cáncer de mama 
 
1.1. Epidemiología y tipos de cáncer de mama  
 
 Las estadísticas actuales sitúan al cáncer de mama como la enfermedad 
oncológica más frecuente y la segunda causa de mortalidad en mujeres de todo el 
mundo, después del cáncer de pulmón74. En 2018, se registraron alrededor de 2 millones 
de casos nuevos y el número de muertes fue alrededor de 600.000, lo cual supone, 
aproximadamente, un 15% de todos los canceres registrados en mujeres75. El pasado 
año 2019, se registraron 300.000 casos nuevos en mujeres y 2670 en hombres, de 
acuerdo con la American Cancer Society76.  
En cuanto a la clasificación de los tipos de cáncer de mama. Es una enfermedad 
heterogénea que se clasifica en diferentes subtipos basados en los estudios pioneros 
llevados a cabo por Sørlie et al.79,80. Así, se definen tumores Luminal A y B, Triple 
negativo, HER2, y Normal-like; además, en una clasificación reciente, no aplicada aun en 





1.2. Cardiotoxicidad en el cáncer de mama 
 
Hasta un 48% de los pacientes oncológicos tratados con antraciclinas desarrollan 
problemas cardiovasculares después del tratamiento106. En el caso de los anticuerpos 
monoclonales como el Trastuzumab, los porcentajes varían del 3% al 7%107. Un estudio 
retrospectivo publicado en el año 2011109 revela como la mayor causa de muerte en 
pacientes diagnosticados con cáncer de mama es debido a eventos cardiovasculares 
consecuencia del tratamiento con quimioterapia. Figura 1. 
Figura 1. Distribución de las causas de muertes registradas en pacientes de cáncer de mama 
a lo largo de los años. CVD: eventos cardiovasculares. La imagen ha sido tomada de Patnaik J, 
et al. 2011.  
 
 El estudio fue llevado a cabo en 63,566 mujeres durante 105 meses. La 
conclusión obtenida fue que mujeres más mayores diagnosticadas con cáncer de mama 
fueron igualmente propensas a morir tanto por la enfermedad oncológica como por 
enfermedades cardiovasculares. Esto pone de manifiesto la importancia de tener un 
seguimiento l cardiológico, tanto durante como a posteriori, del tratamiento con 







3. Mieloma múltiple 
 
3.1. Epidemiología y estadios de la enfermedad 
 
De acuerdo con la American Cancer Society, en 2019 fueron diagnosticados 
32.110 casos nuevos de mieloma multiple (MM): 18.130 hombres y 13.980 mujeres74. 
Los pacientes diagnosticados con MM, en general, fueron mayores de 65 años y solo un 
1% de los casos fueron más jóvenes de 35 años. Los hombres son más propensos a sufrir 
la enfermedad que las mujeres114. 
En algunas ocasiones, los pacientes de MM no responden al tratamiento (se 
hacen refractarios al mismo) y recaen después de haber pasado 60 días de una buena 
respuesta r, aunque en ocasiones la recaída sucede meses o incluso años después de la 
buena respuesta inicial (recidiva)115.  
A la hora de describir los síntomas de la enfermedad se utiliza el acrónimo 
CRAB117. C para el calcio (hipercalcemia), R para describir la disfunción renal, A para la 
anemia y B para la afectación ósea (bones). En cuanto a los estadios de la enfermedad, 
estos son tres y están muy bien detallados en la International Myeloma Working Group 
(IMWG)100,118 
 
3.2 Tratamiento y cardiotoxicidad en el mieloma múltiple 
 
El uso de los inhibidores del proteasoma (PIs) ha revolucionado el tratamiento 
del Mieloma múltiple. A día de hoy, hay tres de esos fármacos aprobados por la FDA: 
Bortezomib (PS-341, Velcade)120, Carfilzomib (PR-171, Kyprolis)121 e Ixazomib 
(MLN9708, Ninlaro)219. 
  Además, hay un grupo de tres PIs de segunda generación que se encuentran en 
fase II/III en ensayos clínicos; son: Oprozomib, Delanzomib y Marizomib. En la siguiente 
imagen se resume a que subunidad del proteasoma van dirigidos (Figura 2). Cabe 
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mencionar que estos PIs se utilizan en combinación con glucocorticoides e 
inmunomoduladores.  
 
Figura 2. Representación esquemática de las subunidades que inhiben cada uno de los PIs. El 
circulo rosa indica la subunidad Caspase-Like (β1), el morado indica la subunidad Trypsin-Like 
(β2) y el verde indica la subunidad Chymotrypsin-Like(β5). 
 
Los efectos secundarios que producen en el corazón no han sido bien estudiados 
desde el principio de su uso en la clínica. Algunos datos revelan que pacientes tratados 
con bortezomib, lenalidomida y dexamethasona presentan arritmias e incluso 
trombosis. En el caso del Carfilzomib en combinación, se ha registrado fallo cardiaco, 
isquemia y tromboembolismo131. 
 
 
4. Enfermedades de rasgo complejo y heredabilidad perdida 
 
La susceptibilidad genética a desarrollar cardiotoxicidad como consecuencia de 
un tratamiento oncológico no es debida a un sólo gen si no, por la suma de los efectos 
de múltiples genes que tienen un efecto discreto132. Incluso en caso donde los pacientes 
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tienen una predisposición genética de sufrir la enfermedad, estos genes tienen baja 
penetrancia y el riesgo a sufrir la enfermedad se ve modificado por otros genes.  
Parte de la variabilidad fenotípica observada en un rasgo complejo en la 
población tiene un origen genético que viene determinado por diferencias genéticas 
entre los individuos en la población y la influencia del medio ambiente en ellos. La 
heredabilidad en sentido amplio, está definida por la proporción de la varianza 
fenotípica explicada por la varianza genotípica; mientras que heredabilidad en sentido 
estricto es la proporción de la variabilidad fenotípica debido al componente genético 
aditivo, excluyendo los determinantes genéticos relacionados con epistasis y 
dominancia genética134. En el análisis de ligamiento, las regiones genómicas asociadas a 
la variabilidad de los fenotipos de rasgo complejo se denominan locus para un carácter 
cuantitativo o QTL. 
Existen discrepancias entre la proporción de la variabilidad fenotípica que se cree 
que es debida a diferencias genéticas y el porcentaje de esa variabilidad que podría 
atribuirse directamente a variaciones genéticas previamente asociadas con este 
fenotipo. A esta discrepancia se la conoce como heredabilidad perdida.  
Cualquier fenotipo de rasgo complejo es el resultado de los efectos de fenotipos 
intermedios, en otras palabras, fenotipos que participan en la fisiopatología y patogenia 
del fenotipo complejo principal se les denomina fenotipos intermedios o subfenotipos, 
los cuales van a formar redes complejas de interacción a diferentes niveles entre 
diferentes procesos que serán los que determinen el fenotipo final: la enfermedad, en 





Figura 3. Los fenotipos intermedios contribuyen a la patogénesis de la enfermedad de 
génesis compleja a través de diferentes niveles: sistémico, orgánico/tejido, celular y 
molecular. Hay múltiples interacciones en cada nivel y entre niveles. Además, todos están 
influenciados por el nivel genético y medioambiental. 
 
La estrategia de dividir la enfermedad en diferentes fenotipos intermedios para 
estudiar su contribución en el componente genético de la enfermedad ha sido 
previamente usada en psiquiatría144.  
 
 
HIPÓTESIS Y OBJETIVOS 
 
Nuestra hipótesis es que parte de la susceptibilidad a desarrollar cardiotoxicidad 
podría explicarse por diferencias en los fenotipos intermedios. Probar esta teoría en 
humanos es muy complicado, por tanto, desarrollamos una cohorte heterogénea de 
ratones a nivel genético y fenotípico, pero con grado de complejidad simplificada y 
también controlada a nivel medio ambiental. Evaluamos la cardiotoxicidad en nuestra 
esta cohorte de ratones que recibió tratamiento quimioterapéutico tras desarrollar 
cáncer de mama. Después, estudiamos diferencias de cardiotoxicidad en función del 
fondo genético, el tipo de terapia recibida y la edad, para después tratar de identificar 
determinantes genéticos asociados a ellos.  
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Para realizar nuestro segundo estudio, utilizamos cardiomiocitos diferenciados a 
partir de células pluripotenciales y testamos diferentes combinaciones de inhibidores 
del proteasoma con inmunomoduladores y glucocorticoides. Siempre imitando 
patrones de tratamiento establecidos en la clínica o ensayos clínicos, para describir 





Este trabajo pretende describir nuevas estrategias para identificar la susceptibilidad a 




Objetivo 1: Identificación de marcadores genéticos y plasmáticos para identificar la 
susceptibilidad a la cardiotoxicidad por antraciclinas mediante la evaluación de 
subfenotipos moleculares asociados a la misma.  
Objetivo 2: Evaluación de la cardiotoxicidad producida por inhibidores del proteasoma 
mediante cultivo de hiPSCs-CMs, con el fin de evaluar la cardiotoxicidad de fármacos 
nuevos y sentar las bases de una estrategia para predecir la cardiotoxicidad individual 









MATERIALES Y MÉTODOS 
 
1. Modelo animal  
 
Se generó una cohorte de ratones a través de una estrategia de retrocruce o 
backcross. Figura 4). Estos ratones desarrollaron cáncer de mama y fueron tratados con 
quimioterapia una vez desarrollaron el tumor. Elegidos de forma estocástica y pareados 
por edades, N=88 ratones hembra fueron tratados con 25mg/kg de doxorrubicina 
(Pfizer). Los ratones recibieron cinco inyecciones intraperitoneales; y otros N=77 
recibieron tratamiento combinado de doxorrubicina a la misma dosis más docetaxel 
25mg/kg cada diez días, también por inyección intraperitoneal. El estudio fue evaluado 
positivamente por el Comité de Bioética de la Universidad de Salamanca. 
Figura 4. Generación de la cohorte de ratones backcross. C57BL/6J153 ratones resistentes a 
desarrollar cáncer de mama se cruzaron con la cepa FVB/N154 ratones susceptibles a 
desarrollar cáncer de mama. La F1 resultante se retrocruzaron con los ratones transgénicos 
FVB/N-Tg(MMTVneu)202Mul/J155 para generar la cohorte de trabajo que denominamos 
backcross (Bx). En ella, cada uno de los ratones es genéticamente único y con unas 
características únicas para fenotipos complejos como son la susceptibilidad y evolución del 
cáncer de mama y la cardiotoxicidad por antraciclinas. 
 
El genotipado de los ratones se llevó a cabo en el Centro Nacional de Genotipado 
(CEGEN) en el nodo presente en el Centro Nacional de Investigaciones Oncológicas 
(CNIO, Madrid), a través de la plataforma Illumina. El número de SNPs que incluye el 
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chip es de 1449 pero de estos, sólo 806 SNPs fueron informativos, es decir que son 
diferentes entre las cepas parentales FVB y C57BL/6 y por tanto pueden diferenciar a los 
ratones del retrocruce.  
 
1.1.  Procesado de los corazones y cuantificación del daño cardiaco.  
 
A partir de los corazones congelados de los ratones se llevaron a cabo los 
siguientes estudios: 
 1) Cuantificación histopatológica del daño a través del sistema ARIOL que es un 
escáner de preparaciones de histología. Para ello se escogieron 5 regiones 
correspondientes a la zona subepicárdica y 5 más de la subendocárdica a un aumento 
de 20X, cuantificándose el área de fibrosis y el área de los cardiomiocitos, como reflejo 
de su grado de hipertrofia.  
2) A partir de 10-15mg de proteínas extraídas de los corazones, se llevó a cabo la 
cuantificación de proteínas implicadas en diversas rutas de interés relacionadas con la 
CDA. El método utilizado fue la tecnología Luminex. Las proteínas elegidas fueron: 
niveles ATR total, CHK1(S345), CHK2(T68), ɤH2AX (S139), P53(S15) y niveles totales de 
MDM2 y P21 mediante el kit 7-plex DNA Damage/Genotoxicity Magnetic Bead Kit 
(Milliplex Map Kit #48-621MAG, Millipore). Otro test utilizado fue el 9 Plex Multi-
Pathway Magnetic Bead Kit (Milliplex Map Kit #48-680MAG), con el que se cuantificaron 
ERK1/2(T185/Y187), P38MAPK(T180/Y182), NFκB(S536), JNK(T183/Y185), AKT(S473), 
P70S6K(T412), CREB(S133), STAT3(S727) y STAT5(Y694/699). Finalmente, cuantificamos 
los niveles de TGFβ-1, TGFβ-2, y TGFβ-3 con Milliplex MAP TGFβ Magnetic-Bead 3 Plex 
Kit (#TGFMAG64K-03, Millipore), así como caspasa 3 y tubulina.  
3) Cuantificamos de la longitud telomérica a través de DNA extraído del 
miocardio  (por el método del fenol-cloroformo220) mediante ensayos de qPCR mediante 
sondas TaqMan158.  
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4) Cuantificación en los niveles de expresión de una serie de miRNAs 
relacionados con diversas patologías cardiacas según la bibliografía. La lista de miRNA 
estudiados se recoge en la Tabla 1. 
Tabla 1: Lista de los miRNAs estudiados.  ID: número de identificación de las 
sondas (Fisher). 
miRNA Sondas ID 
miR-21a-5p hsa-miR-21a-5p 477975_mir 
let-7a-5p hsa-let-7a-5p 478575_mir 




let-7i-5p hsa-let-7i-5p 478375_mir 




let-7b-5p hsa-let-7b-5p 478576_mir 
let-7g-5p hsa-let-7g-5p 478580_mir 
miR-374-5p hsa-miR-374b-5p 478389_mir 
hsa-miR-497-5p hsa-miR-497-5p 478138_mir 
miR-210-3p hsa-miR-210-3p 477970_mir 
miR-100 hsa-miR-100-5p 478224_mir 
miR-130a hsa-miR-130a-3p 477851_mir 




miR-29b hsa-miR-29b-3p 478369_mir 








miR-451 hsa-miR-451a 478107_mir 
miR-361-5p hsa-miR-361-5p 478056_mir 
 
Los miRNA fueron cuantificados en triplicado mediante la plataforma Fluidigm 
BioMark HD Technology en un 96 Dynamic arrays (96-96 Dynamic Array IFC for 
Genotyping #BMK-M-96.96. Link: https://www.fluidigm.com/reagents/genomics/100-
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6499-juno-96-96-genotyping-ifc--1-ifc.  No es más que un Sistema para llevar a cabo la 




Objetivo 1: Identificación de marcadores genéticos y plasmáticos para identificar la 
susceptibilidad a la cardiotoxicidad por antraciclinas mediante la evaluación de 
subfenotipos moleculares asociados a la misma 
 
 La cardiotoxicidad debida a quimioterapia es un efecto adverso común que 
puede ser muy grave y modificar la continuidad del tratamiento oncológico en los 
pacientes que la sufren160.  
 En la primera parte de este trabajo se ha tratado de identificar aquellos pacientes 
más susceptibles de desarrollar CDA. Para ello se han tratado de identificar marcadores 
genéticos161 y biomarcadores en plasma, a partir de subfenotipos que pueden participar 
en la fisiopatología y en la patogenia de la CDA. Como se describe previamente en este 
trabajo, la susceptibilidad a desarrollar CDA crónica tiene un importante componente 
genético,133,166 parte de él puede ser identificado a través de la asociación a 
subfenotipos moleculares ligados a la susceptibilidad a CDA. Para identificar 
subfenotipos de DNA, consideramos que las antraciclinas provocan su cardiotoxicidad a 
través de daño al DNA (genotoxicidad). Por tanto,  diferentes grados de CDA estarían 
relacionados con diferentes niveles de proteínas que participan en rutas moleculares 
implicadas en respuesta al daño al DNA como AKT167 o ɤH2AX168 o moléculas implicadas 
en muerte celular y apoptosis como MDM2 o p53171.  
 También consideramos que diferencias en los niveles y la respuesta de moléculas 
que participan en rutas de señalización relacionadas con patología cardiaca como 
ERK1/2175, p38MAPK177,178 o JNK176 y miRNAs183 o la longitud telomérica185 podrían ser 
subfenotipos moleculares de CDA. El acortamiento telomérico está asociado con estrés 
oxidativo y envejecimiento celular, procesos comunes en las enfermedades 
cardiovasculares ligadas a tratamiento con antraciclinas170.  
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 A través de modelos de regresión múltiple hemos identificado cuales son los 
subfenotipos moleculares con más poder explicativo en la variabilidad fenotípica de la 
CDA entre ratones. Después, determinamos hasta qué punto los QTL asociados con esos 
subfenotipos moleculares podría ayudar a explicar la cardiotoxicidad de algunos de los 
QTL más importantes asociados a CDA en nuestro modelo. De hecho, QTL ligados a 
niveles de expresión de las siguientes proteínas of p70S6K(pT412), JNK (pT183/pY185), 
pCREB(S133), y ɤH2AX(Ser139) explicada que se asociaba con daño cardiaco en ratones 
tratados con quimioterapia. Figura 8. 
 
Figura 8. Resumen de los resultados obtenidos en el análisis de regresión múltiple. Los 
subfenotipos en la región rosa corresponden al tratamiento con doxorrubicina y los de la región 
amarilla corresponden al tratamiento combinado.  
 
Trasladado a pacientes, formas alélicas de RPS6KB1 que codifica P70S6K, y de los 
genes CREB y TUBB, se asociaron con CDA en pacientes. Es interesante señalar que 
P70S6K se ha propuesto como uno de los mejores predictores de cardiotoxicidad, según 
un estudio realizado recientemente.186 al Además, se ha descrito que la expresión del 
gen RPS6KB1 provoca potenciales de acción de menos duración en los cardiomiocitos 
dando lugar a una contractilidad transitoria,8 entre otros efectos181,187. Basándonos en 
estos resultados podría ser interesante en futuros estudios, evaluar la expresión de 
estos genes en otros tratamientos oncológicos y dilucidar si su asocian es específica del 
daño por antraciclinas o si puede ser extrapolado a otros tratamientos. 
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Además, tratamos de identificar pacientes susceptibles de desarrollar CDA a 
través de la determinación de biomarcadores en plasma. Las moléculas evaluadas se 
eligieron en base a su correlación positiva con daño cardiaco en el miocardio de los 
ratones del backcross. En nuestro estudio detectamos en plasma marcadores que 
correlacionaron con daño funcional medido con resonancia magnética cardiaca en 
mismos pacientes. Aun así, nuevos estudios con más pacientes se requieren para validar 
estos resultados.  
 
Objetivo 2: Evaluación de la cardiotoxicidad producida por inhibidores del proteasoma 
mediante cultivo de hiPSCs-CMs, con el fin de evaluar la cardiotoxicidad de fármacos 
nuevos y sentar las bases de una estrategia para predecir la cardiotoxicidad individual 
en el contexto del Mieloma múltiple y otras patologías en que se apliquen estos 
fármacos 
 
 Lo que hace este estudio preliminar atractivo es la descripción en un modelo in 
vitro que podría servir para identificar la susceptibilidad a la cardiotoxicidad por IPs u 
otros fármacos de forma individualizada. En este caso, nos centramos en IPs utilizados 
en el tratamiento del MM tratamiento contra mieloma múltiple.  
 Después de verificar el efecto de cada combinación de fármacos en las líneas 
celulares de MM, se evaluó su cardiotoxicidad in vitro en hiPSCs-CMs. Este tipo de 
estudios buscaba describir cualquier tipo de anormalidad en voltaje o 
contractilidad195,196. En nuestros resultados se observó una correlación entre los valores 
obtenidos en ambos parámetros y no apreciamos ninguna indicación de pro-arritmia 
como se esperaría con el Bortezomib197 o el Carfilzomib131, según datos de la clínica. Sin 
embargo, ante concentraciones altas de estos fármacos, el efecto en los cardiomiocitos 
fue fulminante, se detuvo su actividad; lo que también sucedió con sus análogos 
Oprozomib y Delanzomib.  
 Sobre los valores de voltaje, el marcador de pro-arritmia por excelencia es el 
índice de triangulación, tuvo valores muy bajos en PIs como el marizomib e ixazomib 
tanto en monoterapia como con sus combinaciones con Inmunomoduladores y 
dexametasona. La explicación puede deberse a un acortamiento en la longitud del ciclo 
consecuencia de potenciales de acción que ocurren entes de lo esperado199. 
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 Como excepciones prometedoras encontramos que el Delanzomib en 
combinación con lenalidomida y dexamethasona parecía ser mejor tolerados por los 
cardiomiocitos que en monoterapia. Este estudio coincide con uno llevado a cabo por 
Vogl DT, et al.123 en el cual se describe el limitado efecto cardiotóxico de este PI de nueva 
generación. Además, se sabe que el incremento en la señalización de la ruta de los 
glucocorticoides (GR) es beneficiosa para inhibir la muerte celular por cardiotoxicidad 
debida a quimioterapia202 y mejorar la contractilidad en los cardiomiocitos203.  
 Por otro lado, encontramos el marizomib el cual pareció tener un efecto en la 
línea celular U266B1 y ningún efecto en los cardiomiocitos. Hay varios ensayos clínicos 
que están evaluando este compuesto,125,207 pero los resultados reportados hasta la fecha 
no indican presencia de cardiotoxicidad en los pacientes y si efecto contra la 
enfermedad hematológica. Además, atraviesa la barrera hematoencefálica,208 lo cual 
abre más opciones de tratamiento para otras enfermedades oncológicas que afecten al 




Nuestros estudios en una población backcross de ratón muestran que 
determinantes genéticos y fenotipos intermedios pueden explicar la susceptibilidad a 
sufrir cardiotoxicidad por antraciclinas. 
Además, el uso de hiPSCs-CMs permite testar nuevos compuestos que ayuden a 
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